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Background:  Compromised barrier function and bacterial translocation are common 
complications of short bowel syndrome (SBS) and parenteral nutrition (PN).  Although mucins help 
prevent intestinal bacteria translocation, total mucin production has been shown to decrease during 
PN infusion.  Butyrate administration may be a mucin fortifying strategy as it has been shown to 
increase mucin production in vivo and ex vivo.   
Objective:  We tested the hypothesis that infusion of TPN supplemented with 9 mM butyrate will 
enhance protective goblet cell chemotypes in the small intestine, specifically sulfomucins, that 
enhancement of protective goblet cell chemotypes in the SCFA-supplemented group will be 
observed, since this group also contains 9 mM butyrate, that butyrate-supplemented TPN will have a 
greater effect on the small intestine than the large intestine, while butyrate supplementation at 60 
mM will have a greater effect on the large intestine than the small intestine.  We also hypothesize 
that muc2 mRNA abundance will increase in the small intestine with butyrate and SCFA-
supplemented TPN infusion, whereas colonic muc2 mRNA abundance will increase in the colon 
with 60 mM butyrate administration. 
Methods: Forty-eight hour old piglets underwent 80% proximal jejunuoileal resection and were 
randomized to one of four groups: control total parenteral nutrition (TPN), TPN supplemented 
with 60 mM SCFA (36 mM acetate, 15 mM propionate, and 9 mM butyrate; SCFA), 9 mM butyrate 
(9Bu) or 60 mM butyrate (60Bu).  Animals were further randomized to an acute (12 hour) or chronic 
(72 hour) time point.  muc2 mRNA abundance, total goblet cell number, and total sulfomucin, 
sialomucin, acidomucin, and neutral mucin goblet cell numbers were ascertained. 
Results:  Sulfomucin chemotypes were increased in the jejunal villi of the 9Bu group compared to 
control (treatment main effect, p=0.047).  Acidomucin chemotypes in ileal crypts were greater in the 
60Bu group than the control group (treatment main effect, p=0.038).  In the colonic crypts, SCFA 
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groups tended to have greater acidomucin chemotypes than control at 12h while 60Bu group tended 
to have greater acidomucin chemotypes per depth than control at 72h (p=0.060; Table 2.3).  muc2 
mRNA was increased in jejunal tissues in the 9Bu group compared to control with 270% and 30% 
increases in muc2 mRNA at 12 and 72 hours, respectively (p=0.010).   
Conclusion:  The 9 mM Bu treatment increased protective goblet cell chemotypes and muc2 mRNA 
in the jejunum while 60 mM Bu increased protective goblet cell chemotypes in the ileum and colon.  
The 9Bu treatment was the most effective at upregulating muc2 mRNA abundance and sulfomucin 
chemotypes.  Butyrate-supplemented PN may be a therapeutic strategy for bolstering the epithelial 
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Short bowel syndrome (SBS) is the most common cause of intestinal failure in infants 
(Goulet and Ruemmele, 2006) and occurs in 4.4% of preterm infants with only a 73% to 89.7% 
survival rate (Quiros-Tejeira et al., 2004; Wales et al., 2004).  Treatment often includes nutrition 
management in the form of parenteral nutrition (PN), which can extend the life of a patient with 
SBS for many years (Dudrick et al., 1968; Wilmore and Dudrick, 1968; Dudrick and Allen, 1971).  
However, long-term administration of PN can compromise quality of life and can result in 
potentially fatal primary complications such as parenteral nutrition-associated liver disease 
(PNALD), recurrent sepsis, and uncontrolled fluid losses, or secondary complications such as 
bacterial translocation, barrier dysfunction, muted intestinal adaptation, and multiple organ 
dysfunction syndrome (MODS) (Johnson et al., 1975; Morin et al., 1978; Ford et al., 1984; Deitch, 
1992; Inoue et al., 1993; Conour et al., 2002; Yang et al., 2002; Ziegler et al., 2002; Dahly et al., 2003; 
Kansagra et al., 2003; Wiest and Rath, 2003; Kumpf, 2006; Grau et al., 2007; Jan, 2008).   
Within the first line of defense against invading pathogens—innate immunity—is intestinal 
mucous, made predominantly of the glycoprotein mucin.  Decreases in mucin abundance or  in 
protective goblet cell chemotypes can leave the epithelial barrier exposed to bacteria and bacterial 
products which can lead to bacterial translocation (Gork et al., 1999).  In addition, direct contact of 
harmful luminal contents to the epithelial lining promotes inflammation, which can further impair 
barrier function (Yang et al., 2002; Yang et al., 2008) and increase the risk of bacterial translocation.  
Further, it has been shown that parenteral nutrition-associated liver disease possibly results from 
bacterial translocation (Sondheimer et al., 1998).  Because the liver is responsible for clearing toxins 
from the body, liver disease can lead to MODS.  Bolstering one of the initial defenses, mucin, may 
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improve the outcome of SBS patients by preventing bacteria-induced mucosal inflammation and 
further complicatoins.   
Mucin abundance is decreased by the typical nutritional management of SBS, PN 
administration (Iiboshi et al., 1994; Bertolo et al., 1998; Law et al., 2007).  However, PN increases 
protective goblet cell chemotypes (Conour et al., 2002).  The short chain fatty acid (SCFA) butyrate 
enhances mucin production in vitro and ex vivo (Finnie et al., 1995; Willemsen et al., 2003; Hatayama 
et al., 2007; Burger-van Paassen et al., 2009), but its direct effect on mucin in vivo and its effect via 
parenteral administration has not yet been elucidated.   This study analyzes the effect of parenteral 
butyrate and SCFA administration on both mucin mRNA and goblet cell chemotypes in a SBS 
model piglet receiving total parenteral nutrition (TPN). 
 
THE NEONATAL INTESTINE 
Intestinal Cells 
Four main layers of tissue compose the intestinal wall: the mucosa, submucosa, muscularis 
externa, and serosa (Saladin, 2004).  The mucosa layer is closest to the lumen and is comprised of a 
luminal layer of epithelial cells followed by the lamina propria and muscularis mucosa layers (Madara 
and Trier, 1994).  The anatomy of the small intestine, from the nature of the folds to the surface of 
the cells, creates a vast area that allows for digestion and absorption of nutrients.  The folds of 
Kerckring occur along the mucosa of the small intestine, and upon this surface area are projections 
called villi, fingerlike protrusions of the mucosal layer.  Extending from the surface of each 
absorptive cell of the villi are microvilli which contain the brush border enzymes necessary for 
digestion.  Crypts of Lieberkühn—similar to pores—descend from the epithelium to the muscularis 
mucosa (Saladin, 2004).   
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Stem cells located in the lower half of the crypts differentiate into one of five kinds of 
epithelial cells: enterocytes, goblet cells, enteroendocrine cells, paneth cells, and M cells, also known 
as microfold cells (Leedham et al., 2005).  Epithelial cells migrate from the crypt to the tip of the 
villus where they are sloughed off by luminal contents and consequently digested.  Enterocytes are 
responsible for continuous absorption of macromolecules and micronutrients from the lumen and 
transportation of the contents to the circulation and lymph, and they are present in the villi and the 
upper half of the crypt epithelium (Kimmich and Randles, 1975; Iuldashev et al., 1978; Saladin, 
2004).  Goblet cells are located in these same areas as enterocytes; however, they descend further 
into the crypts and have the primary role of mucin production and secretion (Moe, 1953; Forstner et 
al., 1973).  Enteroendocrine cells are found along the epithelium and are responsible for releasing 
peptide hormones of both endocrine and paracrine function.  Paneth cells are the only epithelial cell 
line present at the base of the crypts and extend about halfway up the crypt walls and secrete 
defensins, lysozyme, and phospholipase to protect against harmful luminal contents (Trier, 1963; Qu 
et al., 1996; Ayabe et al., 2000).  Last, M cells are found in the follicle associated epithelium (FAE) of 
Peyer’s patches in the ileum and are responsible for antigen sampling and transportation (see below; 
Owen and Jones, 1974).   
Epithelial cells are held together by tight junctions which are located between cells at the 
apical end of the cell, and desmosomes, located directly beneath tight junctions.  Tight junctions 
restrict paracellular transport (Claude and Goodenough, 1973) and consist of the specific proteins 
zonula occludens-1 (ZO-1; Stevenson et al., 1986), cingulin (Citi et al., 1988), junctional adhesion 
molecules (JAM; Martin-Padura et al., 1998), claudin-1 and claudin-2 (Furuse et al., 1998), and 
occludin (Furuse et al., 1993).  Desmosomes are more important for cell to cell adhesion than 
paracellular restriction and are comprised of the protein E-cadherin (Boller et al., 1985).  Tight 
junction structure is very plastic in nature and can be modulated by physiological, physical, and 
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pathological occurrences.  For example, intestinal inflammation has been shown to reduce barrier 
function by causing tight junction transmembrane proteins to internalize and by disrupting the 
protein’s membrane affiliations (Bruewer et al., 2003). 
 
Enteric Immune System 
 The intestine has extensive immunological function, as it is in contact with both the external 
environment (e.g. food and ingested bacteria) and the internal resident microbiota.  The innate 
immune system is a highly conserved type of immunity across organisms, and operates as both the 
first line of defense against pathogens and as an activator of the acquired immune system, which is 
present in more advanced organisms and involves recognition of foreign substances from previous 
encounters (Yuan and Walker, 2004).  The intestine bridges to the acquired immune system via M 
cell and dendritic cell interaction.   
The intestinal immune system is termed GALT, or gut associated lymphoid tissue, and 
consists of oval bundles of lymphoid tissue known as Peyer’s patches which are covered by follicular 
associated epithelium (FAE; Figure 1.1).  Harmful luminal products or bacteria are endocytosed or 
phagocytosed, respectively, by M cells in the FAE and are trafficked to the base of the cell (Owen 
and Jones, 1974; Neutra et al., 1996).  The bases of M cells are expanded to form a pocket like 
invaginations containing T cells, B cells, and macrophages (Farstad et al., 1994); however, it has not 
been clearly shown that these lymphocytes and macrophages are within the M cell plasma 
membrane.  In addition, the M cell pocket is only characteristic of a mature M cell; newborn piglets 
have immature M cells that have not yet formed the pocket like invaginations (Kido et al., 2003).  
Below the FAE, in the lamina propria, is the subepithelial dome (SED) which contains strategically 
placed dendritic cells, presumably to begin processing M cell admitted antigens for presentation to T 
cells (Kelsall and Strober, 1996).  Below the SED are lymphoid follicles (Owen, 1977) containing B 
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lymphocyte germinal centers (Butcher et al., 1982).  Between the follicles are the interfollicular 
regions that are rich in T cells and macrophages (Kelsall and Strober, 1996).  Typically, dendritic 
cells are responsible for the connection between the innate immune system and the acquired 
immune system by recognizing antigens engulfed by the M cells and presenting them to T cells 
(Langhoff and Steinman, 1989) located in either the M cell pocket (Pappo, 1989; Pappo et al., 1991), 
the lamina propria, or the nearest mesenteric lymph node (MLN; Holt et al., 1994).  However, M 
cells also have processes that protrude from their basal membrane and extend as far as 10 µm and 
potentially make contact directly to lymphoid tissue (Giannasca et al., 1994).  In addition, epithelial-
associated dendritic cells have been shown to extend between intestinal epithelial cells, forming tight 
junctions with these cells, and directly sampling antigens from the lumen without the help of the M 
cell (Rescigno et al., 2001; Niess et al., 2005).  These epithelium associated dendritic cells are also 
capable of traveling to the MLNs (Schulz et al., 2009).   
Bacterial translocation has been established as a transcellular process, specifically through 
FAE M cells (Grutzkau et al., 1990; Jones et al., 1994; Jensen et al., 1998); however, there has been 
recent conjecture that bacterial translocation may also occur paracellularly (Nadler et al., 2000).  In 
this ex vivo study by Nadler and colleagues, pinocytosis and phagocytosis were alternatively inhibited 
with no change noted in bacterial translocation meaning that paracellular transport is a likely 
mechanism for bacterial translocation.  Although, both mechanisms of transcellular transport were 
not inhibited at the same time meaning that when one is restricted, the other mechanism may 
compensate.  Further research in the area of paracellular bacterial translocation is needed.   
Because M cells function to transport bacteria and bacterial products for immune function, 
they consequently have absent or minimal microvilli and greatly shortened glycocalyx (Bye et al., 
1984; Neutra et al., 1999).  Mucous, a viscoelastic gel-like covering over the intestinal epithelium is 
made mainly from goblet cell mucin secretion.  Because goblet cell secretions could block M cell 
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engulfment, they are rare in the FAE of human intestinal cells and have been precisely calculated to 
account for only 0.5% of the cells in porcine FAE (Fujimura et al., 1992; Beier and Gebert, 1998).  It 
may seem that increases in muc2 mRNA, and potentially more Muc2 protein and mucous 
production, or more protective goblet cell chemotypes would not likely affect bacterial translocation 
since M cells are primed for bacterial engulfment and have few neighboring protective goblet cells. 
However, mucous is still important in preventing bacteria-induced inflammation in the epithelium 
apart from the FAE.  As previously mentioned, inflammation can result in barrier function damage.  
Furthermore, although definitive paracellular transport of bacteria and bacterial products has not 
been established, protective mucin types and mucous abundance are correlated with decreased 
bacterial translocation in vitro and in vivo, demonstrating the advantage of specific mucins in 




Mucins and Intestinal Function 
Mucous is a semi-permeable viscoelastic gel coating that protects the intestinal epithelium 
from enzymatic, chemical, and mechanical damage by providing barrier function making it essential 
in innate immunity.  The main component of mucous is mucin, which is secreted from goblet cells; 
however, mucous also consists of other secretory components that confer protection to the 
intestine.  Secretory immunoglobulin A (sIgA), a mucosal antibody secreted from intestinal plasma 
cells (Perkkio and Savilahti, 1980), is present in the intestinal mucous (Hamer et al., 2009).  Paneth 
cells contribute to intestinal defense by secreting the microbiocidal peptides lysozyme (Fleming, 
1922; Trier, 1963), defensins (Ayabe et al., 2000), and phospholipase (Qu et al., 1996).  In addition to 
mucin, goblet cells secrete intestinal trefoil factor (ITF; Podolsky et al., 1993), a peptide thought to 
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safeguard the epithelial layer by encouraging healing upon insult (Thim, 1989; Wright et al., 1990; 
Alison et al., 1995).  In ITF-deficient mice, the administration of dextran sulfate sodium—an agent 
that typically causes only mild intestinal injury—caused death from severe colitis (Mashimo et al., 
1996).  Goblet cells also secrete resistin-like molecule β (RLMβ ),  a protein that promotes 
inflammation (Nair et al., 2008).  While excessive inflammation can damage the epithelial layer, some 
inflammation is necessary and is a natural reaction against pathogens. 
Mucins are generally categorized into two groups: secreted mucins (gel-forming and non-gel-
forming) and membrane-anchored mucins.  The majority of intestinal mucous is made of secretory 
gel-forming mucins, and contains predominantly Muc2, a mucous protein encoded by the muc2 gene 
(Gum et al., 1989; Griffiths et al., 1990).  Muc2 is generally considered to be a secretory rather than a 
membrane bound mucin, but some have found that Muc2 contributes to two different layers: one 
fraction completely detached from the epithelium that is easily washed away with saline and a 
fraction that is adherent to the epithelium (Johansson et al., 2008).  The loose layer of mucous is 
thickest in the colon and thinnest in the jejunum.  The adherent layer is continuous and firm in the 
colon but is thinner or non-existent in the small intestine (Atuma et al., 2001).   
Mucins are heavily glycosylated proteins composed of approximately 75%-80% carbohydrate 
and 20-25% amino acids (Carlstedt et al., 1993).  While Muc2 contains a significant amount of 
tandemly repeated, heavily O-glycosylated regions (Toribara et al., 1991) made mainly of serine, 
threonine, and proline (Fahim et al., 1987; Huan et al., 1992), the mucin ends are unique and have 
fewer serine and threonine residues and contain more cysteine residues (Gum et al., 1992).  On 
average, there are 4 monosaccharides on the carbohydrate side chains (Carlstedt et al., 1993), which 
sometimes contain sulfate (Carlstedt et al., 1993) and sialic acid (Hansson et al., 1991) residues.   
The structure of mucin is central to its function.  The cysteine-rich ends of mucins serve to 
aid polymerization of mucin monomers into oligomers, which has been demonstrated by treating 
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mucins with disulfide-specific reducing agents and observing a subsequent loss of viscosity and gel-
forming ability in the mucin (Tabachnik et al., 1981).  In addition, the cysteine-rich ends are very 
similar to von Willebrand factor (vWF) (Gum et al., 1994), a glycoprotein found in endothelium, 
essential in blood coagulation.  Cysteine-rich ends are crucial to oligomerization and packaging of 
vWF into granules, suggesting by analogy that cysteine-rich ends may be important to intestinal 
mucin polymeriazation and packaging as well. (Xu et al., 1992).   
Their heavily glycosylated core gives mucins their expanded and viscoelastic structures and 
allows for solubility in the intestinal lumen.  Removal of the carbohydrate moieties results in a 
denatured protein, demonstrating that the glycosylated side chains are essential to mucin structure 
(Shogren et al., 1989).  In addition, it has been calculated that mucins with 2 or more carbohydrate 
residues per side chain results in a 2.5-3 fold increase in size in solution compared to a non-
glycosylated mucin (Shogren et al., 1986).  The expanded structure means that mucins overlap and 
become entangled, giving rise to the viscoelastic properties of mucin (Shogren et al., 1989).  
Viscoelasticity of intestinal mucous is necessary to withstand the mechanical stress of both the 
muscular force of the intestine, such as peristalsis, and the movement of particles across the mucous 
and epithelium.  In other words, the viscoelasticity of mucous ultimately protects the epithelium 
from mechanical damage (Bansil et al., 1995).  Because mucous serves as a physical barrier, it also 
protects the epithelium against chemical and enzymatic damage.  Lastly, the sulfate and sialic acid 
residues create a high density negative surface charge which binds water, further enhancing 
viscoelastic properties. 
In addition to the protection that mucin provides against the chemical, enzymatic, and 
mechanical stress of normal gastrointestinal function, they also provide protection from bacteria 
ingested or residing in the intestine.  First, mucin protects the epithelium by trapping bacteria that 
subsequently get excreted with the loose layer of mucous in the feces.  In a study by Johansson and 
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colleagues (2008), it was found that in the colon, the loose layer of mucin, which is excreted in the 
feces, is colonized by bacteria, while the inner layer is almost devoid of bacteria, possibly reflecting 
the effective barrier mucin provides.  Further, in this study, muc2-/- mice had bacteria in direct 
contact with the colonic epithelium, demonstrating the necessity of mucin in preventing bacterial 
contact with the epithelium and possibly even preventing bacterial translocation (Johansson et al., 
2008).   
 Secondly, mucin serves as a physical barrier that is difficult for the bacteria to break down.  
The type of carbohydrate side chains on mucin plays a role in the protectiveness of the mucin 
against bacterial penetration.  Upon bacterial introduction in vitro to germ-free rat mucin, 
sulfomucins and neutral mucins were 40% and 55% degraded, respectively, at 4 hours while 
sialomucins were 90% degraded at 1 hour and almost completely degraded at 4 hours (Fontaine et 
al., 1998).  Thus, sulfomucins and neutral mucins confer a more protective effect in the intestine 
than sialomucins because they are more slowly degraded by bacteria, therefore the established 
continuum of mucin protection is as follows: sulfomucins > neutral mucins >>> sialomucins.   
An earlier study also suggested the benefit of acidomucins (both sialomucins and 
sulfomucins) over neutral mucins.  The colonization of germ-free rats with rat-specific intestinal 
microbiota triggered an initial release of neutral mucins with a progressive shift towards acidic mucin 
secretion observed over the following 4 months (Enss et al., 1992).  In this study, the researchers 
suggested that the replacement of neutral mucins with acidomucins over this time frame was in 
response to the development of gastrointestinal microbiota and was possibly a form of maturation 
of the gastrointestinal tract (Enss et al., 1992).   
Several studies confirm the protective nature of sulfomucins (Sakata and von Engelhardt, 
1981; Deplancke et al., 2000; Conour et al., 2002; Dawson et al., 2009).  Mice deficient in sulfate 
transporters had higher levels of sialomucin than sulfomucin levels compared to control mice, and 
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these mice had greater susceptibility to toxin-induced colitis and exhibited decreased intestinal 
barrier function (Dawson et al., 2009).  This is most likely attributed to the lack of sulfate residues 
provided intracellularly by sulfate transporters resulting in decreased sulfate addition during post-
translational mucin modification (Dawson et al., 2009).  Further, it has been demonstrated that 
sulfomucins increase in concentration from the duodenum to the colon, mirroring the same pattern 
of bacterial concentration from proximal to distal bowel (Sakata and von Engelhardt, 1981; 
Deplancke and Gaskins, 2001; Conour et al., 2002).  The increase of sulfomucins in areas of higher 
microbial density suggests the importance of sulfomucins in barrier defense against resident and 
infectious microbial populations.   
As previously mentioned, mucins serve to trap bacteria.  The action of trapping bacteria also 
allows bacteria to congregate which has been shown in vitro to aid in the growth of biofilms on fixed 
Caco-2 human epithelial cells (Bollinger et al., 2003).  While this may seem contrary to the purpose 
of trapping bacteria, and while mucous can aid in the biofilm formation of harmful species 
(Bollinger et al., 2003), biofilms have also been shown to be beneficial to the intestine and host 
health (Jones and Versalovic, 2009).  In addition to binding each other, bacteria bind receptor sites 
on mucin which serve to compete with bacterial receptor sites on the underlying epithelium 
(Wadolkowski et al., 1988; Conway et al., 1990).  Scientists have demonstrated that some pathogens 
have adapted to using these binding sites as temporary attachment while moving towards the 
epithelial layer (Drumm et al., 1988; McCormick et al., 1988; Conway et al., 1990).  These same 
scientists also demonstrated that the pathogens lost their piliation, binding ability to epithelial cells, 
or the ability to tumble and swim after colonizing intestinal mucous.  So it may be that intestinal 
mucous aids pathogens in reaching the epithelium, but may inhibit the bacteria’s ability to actually 
bind to the epithelium.  If enough mucous is present, it is likely that excretion of the pathogens 
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while they are attached to the mucous can occur before the rate of replication of pathogens becomes 
threatening (Forstner, 1994). 
 
Synthesis and Excretion of Mucins 
Muc2 production appears to occur solely in goblet cells (Van Klinken et al., 1995).  Within 
the goblet cells, mucins are synthesized similarly to most packaged secretory glycoproteins.  They are 
first synthesized on ribosomes and then transported to the rough endoplasmic reticulum (RER) 
where they are folded and oligomerized.  Carbohydrate side chain additions begin cotranslationally 
via sulfotransferases, sialytransferases, and glycosyltransferases at the ribosomal level, continue at the 
RER (Strous, 1979), and the main carbohydrate side chain additions occur within the Golgi complex 
(Dekker and Strous, 1990).  Condensing granules containing the mucins bud off from the trans-
Golgi and mucins are increasingly condensed with the help of increasing intragranular 
concentrations of cationic calcium (Paz et al., 2003).  As goblet cells mature, granules are separated 
from the inner surface of the plasma membrane by a thin web of actin filaments.  The mucins are 
released when the granule’s membrane fuses with the cell plasma membrane, creating a fusion pore, 
and then releasing the mucin via exocytosis through a dialating pore (Breckenridge and Almers, 
1987).  This process can be either constitutive or regulated.   
In constitutive pathways, granules are transported directly to the plasma membrane and 
release mucin without any signal, only requiring contact with the membrane.  Several cell types have 
been shown to release small amounts of glycoprotein continuously via the constitutive pathway 
while also retaining the ability to upregulate mucin secretion in response to an environmental signal 
(regulated pathway; Gumbiner and Kelly, 1982; Sporn et al., 1986; Arvan and Chang, 1987; Burgess 
and Kelly, 1987).  The mechanism regarding the movement of mucins out of granules is not fully 
elucidated, but one hypothesis is that the smaller calcium ions escape first after the fusion pore 
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opens, leaving highly negative mucins to strongly repel each other,  which pushes them out of the 
granule (Forstner, 1994).  The hydrophilic mucins then become a viscous gel.  Complete refilling of 
the goblet cell takes approximately 60-120 minutes (Specian et al., 1990).  Once full, the goblet cell is 
then ready to release more mucin.  The protection provided by mucous is most important in those 
with intestinal problems, such as intestinal failure, since many of these conditions predispose the 
intestine to further damaging events such as bacterial translocation into the systemic circulation or 
organs.   
 
INTESTINAL FAILURE 
Etiology of Intestinal Failure  
Intestinal failure (IF) is defined as the critical reduction of functional bowel below the 
minimum amount needed for adequate absorption of the basic metabolic requirement without oral 
or intravaneous supplementation (Jeejeebhoy, 2005).  This decrease in function can result in severe 
malabsorption without supplementation and can be caused either by short bowel syndrome (SBS) 
which results from surgical resection of the bowel or intestinal failure which is non-functioning (but 
not necrotic) sections of the bowel that don’t necessarily need to be removed.  Other causes of IF, 
besides SBS, include severe extended Hirschsprung’s disease (a motility disorder), chronic intestinal 
pseudo-obstruction, mesenteric venous thrombosis, necrotizing enterocolitis, gastroschisis, midgut 
volvulus, desmoids tumor, intestinal atresia, trauma, and Crohn’s disease (Hyman et al., 1994; 
Nishida et al., 2002).  Conditions like these in which functional surface area, motility and/or 
obstruction are issues, intravenous supplementation is often necessary since enteral nutrition (EN) 
would not be viable.  In the past, severe malabsorption plagued individuals with IF.  However, 
patients with intestinal failure are now living longer due to the advent of PN in the mid-1970’s and 
vast improvements to PN over the last 3 decades (Langnas, 2008).   
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Intestinal Failure in Infants 
IF is more common in preterm infants than term infants, as preterm infants typically suffer 
from decreased gastric motility, fat malabsorption, and digestive enzyme deficiencies such as lactase 
deficiency (Klaus and Fanaroff, 2001; American Academy of Pediatrics Committee on Nutrition, 
2004; MacLean and Fink, 1980).  This means the immature gastrointestinal system of a premature 
infant is likely predisposed to  intestinal failure.  Intestinal insults requiring resection can occur 
prenatally, neonatally, or postnatally.  Prenatal etiologies of IF include atresia, malrotation, midgut 
volvulus, segmental volvulus, abdominal wall defects, gastroschisis, and extensive Hirschsprung’s 
disease.  Midgut volvulus can occur during both neonatal and postnatal development, especially in a 
preterm infant whose gastrointestinal system is still developing.  Other neonatal etiologies of IF 
include necrotizing enterocolitis, arterial thrombosis, and venous thrombosis.  Postnatal origins of 
IF include complicated intussusceptions, arterial thrombosis, inflammatory bowel disease, post-




SBS has a relatively low incidence of about 3.1 per 1000 of term infants and 43.6 per 1000 of 
premature infants (Wales et al., 2004).  There are many complications of SBS that are life-
threatening, and the survival rates are alarmingly low, with only 73% to 89.7% of infants surviving 
(Quiros-Tejeira et al., 2004; Wales et al., 2004; Goulet et al., 2005).  Better survival rates are 
significantly associated with remaining post-resection bowel lengths >38 cm, remaining ileocecal 
valve, remaining entire colon, and with primary anastomosis rather than an ostomy performed 
during resection (Quiros-Tejeira et al., 2004).  Additionally, ostomy reversal is associated with 
increased survival (Quiros-Tejeira et al., 2004). 
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One of the functional complications of SBS is reduced digestive and absorptive capacity.  
SBS patients have decreased absorption of all nutrients, even easily digested carbohydrates (Olesen 
et al., 1999).  Oftentimes, management of decreased absorption involves PN since most premature 
infants have neither the reflexes to suckle nor a mature gastrointestinal system to absorb nutrients 
from enteral nutrition (EN) delivered via tube feedings.  Unfortunately, though PN has prolonged 
the lives of many infants suffering from SBS, it can cause further declines in intestinal function and 
can create many other complications by its administration.  PN is associated with both 
morphological and functional decline of the intestine, termed intestinal atrophy (Johnson et al., 
1975; Inoue et al., 1993).  PN can have life threatening complications associated with long term use 
such as liver disease, septicemia or bacterial translocation, or loss of venous access (Pierro et al., 
1996; Sondheimer et al., 1998; de Buys Roessingh et al., 2008).  Fluid balance is also an issue in SBS 
patients depending on what part and how much of the intestine was resected.  PNALD is most 
commonly related to cholestasis in the pediatric population and has been shown to occur in 67% of 
infants on long term PN after intestinal resection of which 17% progressed to liver failure 
(Sondheimer et al., 1998).  In this study, bacterial or fungal infection of the blood, urine, peritoneal 
fluid, cellulitis aspirate, or cerebrospinal fluid preceded all instances of cholestasis, with most of 
these bacteria implicated in infection being common gastrointestinal bacteria, leading one to believe 
that bacterial translocation could have been the factor in some or many of these cases of cholestasis 
and liver failure (Sondheimer et al., 1998).   
 
Secondary Complications 
Bacterial translocation can be a life-threatening secondary complication of either SBS and/or 
PN administration and is the passage of viable or non-viable bacteria and bacterial products from 
the intestinal lumen through the epithelium and into the mesenteric lymph nodes, liver, spleen, 
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kidney, and bloodstream (Wells et al., 1988; Berg, 1999).  Some researchers have found increased 
rates of bacterial translocation in rats receiving TPN compared to rats fed either rat chow ad libitum 
or TPN solution orally (Alverdy et al., 1988; Eizaguirre et al., 2001).  However, other groups have 
found that TPN reduces barrier function but does not increase bacterial translocation in piglets 
(Nakasaki et al., 1998; Kansagra et al., 2003).  As mentioned above, Sondheimer and colleagues 
(1998) speculated that bacterial translocation is a likely cause of cholestasis and PNALD.  Bacterial 
translocation has been associated with MODS in other studies as well (Deitch, 1990; Sullivan et al., 
1991; Zhi-Yong et al., 1992; Fukushima et al., 1995).  The risk of bacterial translocation has been 
proposed to increase due to decreased epithelial barrier function (see below) caused by PN 
administration (Deitch et al., 1995) .   
It has been recently demonstrated that bacterial translocation is also correlated with small 
bowel bacterial overgrowth (SBBO; Cole et al., 2010).  The mechanisms are not necessarily mutually 
exclusive, although the relationship between barrier function, SBBO, and bacterial translocation has 
not been clearly defined.  SBBO is an increase in the total number of bacteria or of certain bacteria 
and can result in nutrient or micronutrient malabsorption (e.g. Vitamin B12), gas generation with 
bloating, abdominal pain, diarrhea, altered motility, and kidney stones.  SBBO is a complication of 
both SBS and PN and may decrease the effectiveness of weaning patients off of PN.  Inflammation 
is often a result of SBBO, either due to certain bacterial species igniting an inflammatory response 
once entering the mucosa, or the host’s overreaction to absorbed bacterial antigens (Dibaise et al., 
2006).  TPN has specifically been shown to predispose neonatal piglets to overgrowth of Clostridium 
perfringens, a detrimental bacteria that has been implicated in bacterial translocation (Meddah et al., 
2001; Deplancke et al., 2002).  
Mucosal inflammation may contribute to the pathogenesis of bacterial translocation.  Direct 
contact of harmful luminal contents to the epithelial lining promotes inflammation which can 
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further impair barrier function (Yang et al., 2002; Yang et al., 2008) and potentially increase the risk 
of bacterial translocation.   Activation of pro-inflammatory cytokines from leukocytes, macrophages, 
and mast cells (Saladin, 2004) has been shown to impair mucosal integrity and barrier function by 
negatively affecting tight junction proteins (Bruewer et al., 2003). 
Adequate mucin content is essential for proper barrier function and decreased mucin 
content can increase the risk of bacterial translocation.  Dawson and colleagues (2009) found that 
sulfate transporter (NaS1) deficient (NaS-/-) mice had a marked decrease in sulfomucin content.  
Without a correctly functioning NaS1 transporter, there are fewer sulfate residues available for 
mucin sulfation.  NaS-/- mice had a significant 24% increase in macromolecule permeability.  Upon 
infection with Campylobacter jejuni, 60% of NaS1-/- mice experienced bacterial translocation presenting 
with Campylobacter jejuni in the liver three days after infection while none of the NaS1+/+ mice 
presented with bacterial translocation.  Interestingly, the NaS1-/- and NaS1+/+ mice had similar 
mucosal integrity against resident microbiota, indicating that the decrease in barrier function was 
only in regards to pathogenic bacterial infection.  Along with the decrease in sulfomucin content, an 
increase in sialomucin content of the NaS1-/- mice was noted.  However, mRNA levels of mucins 
normally expressed in the mouse ileum were unchanged, demonstrating that any role that mucin 
levels played in increased bacterial translocation and intestinal macromolecular permeability in the 
NaS1-/- mice was likely related to a decrease in the sulfomucin to sialomucin ratio (Dawson et al., 
2009).  However, total mucin production was not measured; thus, increases in bacterial translocation 
in the NaS1-/- mice could be due to total decreased mucin abundance rather than solely decreased 
relative sulfomucin content.   
The relationship between inflammation and sulfomucins has also been investigated.  Muc2-/- 
mice downregulate several genes, including essential mucin synthesis enzymes such as 
sulfotransferases (Yang et al., 2008).  Downregulation of sulfotransferases will result in decreases in 
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sulfomucin content.  This study also demonstrated that Muc2-/- mice developed tumors through an 
inflammation linked pathway and that Muc2 deficiency resulted in subclinical chronic inflammation 
(Yang et al., 2008).  Makkink and colleagues (2002) discovered that IL-10-/- mice had sulfate depleted 
mucins compared to control mice, and that IL-10-/- mice had correspondingly inflamed colons.  IL-
10 is an anti-inflammatory cytokine first described in 1989 (Fiorentino et al., 1989).  The lack of IL-
10 could easily cause inflammatory conditions such as inflammatory bowel disease (IBD) or colitis, 
and Makkink and colleagues’ findings suggest that decreased mucin sulfation could be part of the 
mechanism by which intestinal inflammatory conditions arise.  Evidence also demonstrates that 
administration of IL-10 can decrease TPN-associated declines in tight junction proteins in mice (Sun 
et al., 2008), suggesting that a pro-inflammatory response is at least partly responsible for reduced 
barrier function, either by tight junction dysfunction or by decreases in mucin sulfation. 
 
Mucins, Bowel Resection, and Nutrition Support 
The fractional synthetic rate (FSR) is the rate of incorporation of a precursor into a product 
per unit of product mass and has been used in many studies to analyze protein synthesis and 
incorporation.  The FSR of Muc2 in enterally fed human preterm infants after small bowel resection 
was 67.2%, which is one of the highest FSRs determined in humans to date.  This was assessed by 
analyzing labeled threonine incorporation into mucins (Schaart et al., 2009).   
The effect of nutritional support on the rate of mucin synthesis is debated.  Conour and 
collegues (2002) found an increase in the number of acidomucin expressing goblet cells in newborn 
piglets administered TPN.  However, they did not quantify mucin abundance, so mucin decreases 
may be happening concomitantly with goblet cell number stasis or increases.   
Recent reports demonstrated definitive decreases in total mucin content or mucin 
production with TPN administration.  After administration of fluorescin isothiocyanate (FITC)-
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dextran through a gastroduodenal tube, FITC-dextran descended between the villi in the TPN 
administered rats while increased mucous gel in the chow-fed group prevented the FITC-dextran 
dye from filling the inter-villi spaces and retained the dye to the lumen area (Iiboshi et al., 1994) 
demonstrating the increased mucous gel in the chow fed rats.  This group also found that FITC-
dextran plasma levels were elevated in TPN-administered rats compared to chow-fed rats, indicating 
increased permeability in the intestines of rats receiving TPN.  Another study in which rats were 
administered TPN intravenously or fed with the elemental TPN solution orally, epithelial bound 
mucin and mucin within the goblet cells was significantly decreased in the jejunum, with a similar 
trend seen in the ileum (Spaeth et al., 1994).  In addition to nutrition support, micronutrient 
supplementation affects mucin production as well.  Comparing adequate threonine EN piglets, 
adequate threonine PN piglets, and deficient threonine EN piglets, PN resulted in lower mucin 
production in the duodenum, jejunum, and colon (Law et al., 2007).   
Lastly, if nutrition support is not tolerated, mucin production can ultimately be hindered in 
an infant with SBS.  If a preterm infant is in a state of protein-energy malnutrition, the infant can 
have decreased mucin production, resulting in increased susceptibility to bacterial translocation and 
infection (Sherman et al., 1985).     
 
MANAGEMENT OF INTESTINAL FAILURE 
The main goals in nutritional and medical management of intestinal failure are to maintain 
fluid, electrolyte and nutrient balances and to reduce side effects of treatment.  Managing SBS in 
infants is critical as an infant is undergoing rapid development and has high nutritional requirements.  
Further, preterm infants have increased nutritional and medical needs because they have to catch up 
in growth to their term counterpart.  Nutritional supplementation is based on the etiology of 
intestinal failure, the extent and location of resection, if resected, and the clinical lab values of the 
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patient to ascertain vitamin, mineral, and macronutrient deficiencies.  Medical management often 
includes drug therapies such as anti-motility agents to allow the intestine adequate time for digestion 
and absorption.  Intestinal transplantation or bowel lengthening procedures may be considered 
when long term TPN complications have occurred (O'Keefe et al., 2006; Jan, 2008).   
EN in patients with compromised intestinal function is preferred, if tolerated, to avoid the 
complications associated with PN.  If an infant is placed on PN, then management should include as 
much EN as possible to prevent PN-associated atrophy, PN dependence, and the aforementioned 
PN complications.  Intestinal adaptation is the ability of the intestine to increase absorptive area and 
to recover functional abilities of this area to adapt for the loss of intestine post-resection (Althausen 
et al., 1950; Dowling and Booth, 1966; Bell et al., 1973; Stein and Wise, 1978; Curtis et al., 1984).  
Unfortunately, PN administration nullifies intestinal adaptation post-resection due to the lack of 
luminal stimulation provided by oral or enteral feeding (Morin et al., 1978; Ford et al., 1984; Ziegler 
et al., 2002).  Dahly and colleagues (2003) demonstrated after 70% midjejunoileal resection that rats 
administered TPN had significantly greater mucosal hyperplasia by 8 hours, continuing through 7 
days post-resection compared to transection controls.  However, orally fed resected rats had an 
enhanced adaptive response compared to the rats administered TPN.  This study is an example of 
intestinal adaptation occurring even with the administration of PN, but it should be noted that the 
orally fed rats still experienced greater adaptation demonstrating the benefit of luminal stimulation 
that EN or oral diets provide.   
Threonine is an extremely important part of management in the SBS infant.  The mucin core 
is made of mostly serine, threonine, and proline residues, thus these amino acids are essential for 
adequate mucin production.  Studies with rats have been conducted to test mucin production with 
reduced threonine intake which have resulted in steady production of muc2 mRNA but decreases in 
mucin protein abundance, demonstrating that the effect of reduced threonine availability is at the 
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translational level of mucin production (Faure et al., 2005).  Deficient threonine administration in 
piglets results in decreased mucin accumulation in the duodenum and colon compared to the 
adequate threonine fed counterparts (Law et al., 2007).  In this study, adequate threonine resulted in 
stable numbers of goblet cells; however, these goblet cells were hypertrophied—or filled with more 
mucin—compared to deficient threonine fed piglets.  In addition, adequate threonine goblet cells 
had more heterozygous chemotypes or contained a greater mix of mucins (Law et al., 2007).  These 
studies suggest that adequate threonine supplementation plays a role in appropriate mucin 
production. 
Altogether, PN has many basic complications; it reduces barrier function, promotes SBBO, 
decreases mucin abundance and ultimately increases the risk of bacterial translocation across the 
intestinal mucosa.  The interconnected nature of inflammation, mucins, SBBO and barrier function 
in the process of bacterial translocation is evident, and as in all disease, prevention is the ideal 
management.  Provision of EN in tolerable amounts is the best management for SBS as it will help 
to preserve mucosal integrity, barrier function, and mucin production, which together will reduce the 
risk of inflammation and bacterial translocation.   
 
MODULATION OF MUCIN PRODUCTION 
Modulation via Stress, Nutritional Supplementation, and Growth Factors 
As just discussed, nutrition support and threonine can both affect the amount and type of 
mucin produced.  Mucin can be affected by stress and other dietary factors as well.  Mice exposed to 
repeated cold stress initially had an increase in mucin glycoprotein content after one stress exposure; 
however, goblet cell numbers were significantly decreased after just one stress exposure (Pfeiffer et 
al., 2001).  This suggests that goblet cells can increase the rate in which they produce mucin in 
response to stress and become hypertrophied, or engorged, with mucin.  Because cell development, 
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differentiation, and travel take a couple of days, hypertrophy is the most expected response to 
increase mucin in acute time frames in situations of normal proliferation.  Even though stress elicits 
a beneficial response in mucin production, stress also causes a decrease in total goblet cell number.  
This study highlights the importance of reducing stress on an infant with intestinal failure so that 
goblet cell number is not reduced.  In addition, more research needs to be conducted on how to 
increase mucin production without inducing goblet cell-reducing stress.  One of these methods is by 
butyrate administration which will be discussed shortly.   
Fiber can modulate mucin production.  Rats that were administered TPN intravenously or 
fed with the TPN solution orally showed significantly decreased epithelial bound mucin and mucin 
within the goblet cells in the jejunum and the ileum.  However, upon administration of 3.3 g 
cellulose per day, mucin concentration levels tend to increase, demonstrating that certain fiber may 
upregulate mucin production.  Celluose, however, decreased unadhered luminal mucin abundance, 
probably because cellulose administration decreased transit time, removing unbound luminal mucin 
(Spaeth et al., 1994). 
As discussed above, adequate provision of dietary threonine is crucial in intestinal mucin 
synthesis.  Increasing oral threonine intake to 150% of requirements significantly increases mucin 
production in the jejunum (Faure et al., 2005).  Another potential dietary modulator in mucin 
production is β-casomorphin-7, a milk degradation peptide resulting from the digestion of β-casein, 
which has been show to increase mucin production in vitro in rat and human goblet cells, 
demonstrating the potential of dairy products to improve mucosal protective function (Zoghbi et al., 
2006).   
Along with nutrition supplementation, growth factors—such as epidermal growth factor 
(EGF)—are important for intestinal growth.  EGF is important for cell growth, proliferation, and 
differentiation (Cohen and Carpenter, 1975), and when provided luminally, decreases PN-associated 
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atrophy in rats administered TPN.  In addition, EGF accelerates goblet cell maturation and mucin 
production and normalizes expression of tight junction proteins, all of which improve intestinal 
barrier function (Clark et al., 2006).   
 
Modulation via the Short Chain Fatty Acid, Butyrate 
Short chain fatty acids (SCFAs) are a subgroup of fatty acids including acetic, propionic, 
isobutyric, butyric, isovaleric, valeric, and caproic acids.  The salts or ester of these acids are acetate, 
propionate, isobutyrate, butyrate, isovalerate, valerate, and caproate, respectively.  The latter are 
produced in vivo by fermentation of non-starch polysaccharides such as hemiceulloses, pectin, gums, 
and mucilages by the anaerobic microflora of the cecum and colon.  The main SCFAs produced are 
acetate, propionate, and butyrate, which make up 83% of endogenous SCFAs.  SCFAs in human 
colon are generally found to be at a 60:25:15 molar ratio of acetate, propionate, and butyrate, 
respectively (Cummings, 1984; Cummings and Englyst, 1987; Bourquin et al., 1992).  Fermentative 
end products, however, can be influenced by the type of fermentable substrate available (Mortensen 
et al., 1988; Bourquin et al., 1992), the type of microbial species present in the intestine (Macfarlane 
and Gibson, 1995), and by intestinal transit time (Macfarlane et al., 1992).  The opposite is also true, 
in that the type of fermentable substrate provided can influence the microbiota present (Wang and 
Gibson, 1993).  Thus, the type of fiber, a common source of SFCA production, chosen to 
supplement EN or PN is important. 
SCFAs can contribute about 10% of maintenance energy requirements in pigs (Imoto and 
Namioka, 1978).  The production is hypothesized to be similar in humans due to the similarity 
between human and pig gastrointestinal tracts (Sangild, 2006).  The energy contribution of SCFAs in 
humans has been estimated at about 10-15% (McNeil, 1984).  Butyrate is preferentially absorbed 
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over propionate and acetate at a ratio of 90:30:50, and approximately 70-90% of butyrate produced 
in the intestines is used solely by the intestinal epithelium (Cummings, 1984).   
Butryate has been shown in vitro to modulate muc2 expression (Augenlicht et al., 2003; 
Willemsen et al., 2003; Gaudier et al., 2004; Hatayama et al., 2007; Burger-van Paassen et al., 2009).  
Paradoxically, low levels (1-2 mM) of butyrate stimulate muc2 expression (Willemsen et al., 2003; 
Hatayama et al., 2007; Burger-van Paassen et al., 2009), while higher levels of butyrate (5 mM-15 
mM) either halt butyrate-stimulated increases of muc2 expression or even trigger mucous secretion 
(Barcelo et al., 2000; Burger-van Paassen et al., 2009).  Bathing the human colon cancer cell line, 
LS174T, in 1-2 mM butyrate for 36 hours results in a 2-fold increase in muc2 mRNA and an 8-fold 
increase in Muc2 protein (Hatayama et al., 2007).  This was corroborated by Burger-van Passaan and 
colleagues (2009) when 1 mM butyrate produced a 2-fold increase in muc2 mRNA levels when 
administered to LS174T cells.  Also in this study, 5-15 mM butyrate showed a return of muc2 mRNA 
to basal levels.  Additionally, 0.05 mM to 1 mM butyrate results in increased muc2 expression in 
monolayers of T84 cells, and cocultures of T84 and LS174T cells with CCD-18Co cells (Willemsen 
et al., 2003).  In this study, butyrate was also shown to significantly increase prostaglandin E1 
(PGE1) and decrease prostaglandin E2 (PGE2) concentrations in all dosage groups of cocultured 
cells.  Prostaglandins are lipid compounds that come from the eicosanoid family of paracrine 
secretion (Saladin, 2004).  They have been implicated in the regulation of mucous secretion 
(Plaisancie et al., 1998) and have been shown to be released from myofibroblasts, or a cell similar to 
both muscle and collagen, underneath the epithelial layer (Mahida et al., 1997).  An increased 
PGE1/PGE2 ratio has been thought to be beneficial because PGE1 is more potent than PGE2 at 
stimulating muc2 expression in vitro (Willemsen et al., 2003).   
Butyrate does not produce stimulatory effects in muc2 expression in all cell lines.  muc2 
expression is actually reduced upon butyrate bathing in Cl.16E cells (Augenlicht et al., 2003), a clonal 
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derivative of HT29 cells that are polarized and characterized by expression of the muc2 gene and 
mucin synthesis and secretion (Augeron and Laboisse, 1984; Capon et al., 1992; Velcich et al., 1995).  
Upon standard culturing of the Cl.16E cells, muc2 accumulated at day 7 and increased to a maximum 
level at day 15.  At this point, these cells were treated with 5 mM butyrate which resulted in a 50% 
reduction in muc2 mRNA levels and a decrease in Muc2 apomucin after 24 hours (Augenlicht et al., 
2003).  These results seem to indicate that butyrate has a negative effect on goblet cells; however, the 
results can be explained by the butyrate concentration used and by referring to studies by others.  
Augenlicht and colleagues consistently used butyrate at the concentration of 5 mM, which as 
previously mentioned, has been shown to be inhibitory on muc2 expression (Burger-van Paassen et 
al., 2009).  Also, Gaudier and colleagues (2004) found that in a glucose rich medium, Cl.16E cells 
show no increase in muc2 expression upon 2 mM butyrate treatment; however, in the absence of 
glucose, muc2 expression increased 23-fold above basal level.  Thus, the metabolism of butyrate as a 
carbon source may play a role in the induction of Muc2 production.  Augenlicht and colleagues 
(2003) bathed their Cl.16E cells in Dulbecco’s Modified Eagle Medium (DMEM) which depending 
on the solution, may contain glucose.  Because the presence of glucose in butyrate administration 
also effects muc2 expression (Gaudier et al., 2004), it is possible that the lack of effect of butyrate on 
Muc2 levels found by Augenlicht and colleagues was due to the potential presence of glucose in the 
cell medium.   
Thus, while 1 and 2 mM butyrate levels increase muc2 expression, 5 mM butyrate 
administration has been shown to reduce muc2 mRNA expression to baseline levels (Augenlicht et 
al., 2003; Burger-van Paassen et al., 2009).  In addition to muc2 expression and mucin production, 
butyrate affects mucin secretion.  Barcelo and colleagues (2000) demonstrated in vivo that 5 mM 
luminal butyrate administration more than doubled mucin secretion in isolated vascularly perfused 
rat colons.  Mucins are secreted as protective measure in the intestine, and 5 mM butyrate appears to 
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trigger that protective response because that level is possibly perceived by the intestine as damaging 
or butyrate may serve as a signal for regulated mucin secretion. 
One ex vivo study analyzed the effects of butyrate administration on mucin production.  
Butyrate administration of 0.1 mM resulted in a 476% mucin synthesis increase in comparison to the 
control tissue in fresh human colonic biopsies.  The increase was nullified in the presence of sodium 
bromo-octanoate (an inhibitor of beta-oxidation), which reduces the ability for cells to metabolize 
fatty acids such as butyrate, furthering the hypothesis that metabolism of butyrate by colonocytes is 
an important mechanism in mucin synthesis (Finnie et al., 1995).    
There have not been any in vivo studies conducted analyzing the effects of butyrate 
administration on mucin production, nor have there been any studies analyzing parenteral butyrate 
administration on mucin production, but butyrate has had strong positive effects on mucin 
production when administered luminally in vitro and ex vivo.  The one in vivo study by Barcelo and 
colleagues did not ascertain the affects of luminal butyrate on mucin production or muc2 expression; 
but studies in which fiber was administered in vivo (as previously discussed, fiber fermented by 
enteric bacteria produce short chain fatty acids) mucin production was increased.  Satchithanandam 
and colleagues (1996) found that rats fed 10% psyllium had increased colonic luminal mucin, or 
loosely bound mucin.  They also suggest that total mucin levels—which include membrane adherent 
mucins—were increased, but their determination methods of total mucin included protein assays of 
the scrapings of the entire mucosal layer (Satchithanandam et al., 1996).  Increases in protein content 
in this case could be due to increases in villus height or other mucosal factors as butyrate positively 
affects factors other than mucin when administered luminally in vivo (Scheppach et al., 1992; 
Scheppach et al., 1997; Andoh et al., 1999; Vernia et al., 2000).  Gaudier and colleagues have shown 
that cells may need to metabolize butyrate to increase mucin production and muc2 expression; 
however, since butyrate positively affects so many factors when administered luminally in vivo (in 
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which glucose availability cannot be eliminated), butyrate may still be able to produce positive effects 
in the presence of glucose.   
Administration of butyrate parenterally has been shown to enhance several indices of the 
intestinal structure and function.  Parenterally provided butyrate enchances glucose transporter-2 (glut-2) 
mRNA, sodium glucose transporter-1(sglt-1) mRNA, Na+,K+-adenosine triphosphatase (Na+,K+ATPase) 
mRNA (a critical  basolateral enterocyte transporter), proglucagon mRNA (a precursor to GLP-2 and 
incretins), plasma GLP-2 (an intestinotrophic peptide), glucose absorption, villus height, 
proliferation and has been shown to decrease apoptosis (Tappenden et al., 1997; Tappenden and 
McBurney, 1998; Bartholome et al., 2004).  Because of the positive effects of butyrate seen in both 
luminal and parenteral administration, parenteral butyrate and SCFA administration holds promise 
as an intestinal mucin modulator as well, potentially providing protection from intestinal damage and 
bacterial translocation.  This is the first study to describe the effects of parenterally supplied butyrate 







Protective mucins are a crucial part of intestinal barrier defense.  Mucins are even more 
important in neonates with SBS on PN since both SBS and PN increase the risk for bacterial 
translocation. 
Several nutritional modulators of mucin production have been studied, with butyrate being 
effective in upregulating mucin production in vitro and ex vivo; however the effect of butyrate in vivo is 
unknown.  This research aims to analyze the effect of parenteral butyrate administration on mucin-
producing goblet cell chemotypes in the small and large intestine using a PN-supported neonatal 
piglet SBS model.  The data from this research explores the following: 
1)  the effects of SCFA-supplemented TPN on goblet cell chemotypes and  
 muc2 mRNA in a massive small bowel resection neonatal piglet model; 
 2) the effects of butyrate-supplemented TPN, at doses of 9 mM and 60 mM, on  
  goblet cell chemotypesand muc2 mRNA in a massive small bowel resection neonatal  
  piglet model; 
Because butyrate has been documented to improve so many factors of gastrointestinal 
structure and function, we hypothesize that infusion of TPN supplemented with 9 mM butyrate will 
enhance protective goblet cell chemotypes in the small intestine, specifically sulfomucins.  Similarly, 
we expect enhancement of protective goblet cell chemotypes in the SCFA-supplemented group too, 
since this group also contains 9 mM butyrate.  Further, we hypothesize that butyrate-supplemented 
TPN will have a greater effect on the small intestine than the large intestine, while butyrate 
supplementation at 60 mM will have a greater effect on the large intestine than the small intestine 
because the large intestine is more accustomed to SCFA and may need a larger dose to confer a 
benefit.  As such, we expect muc2 mRNA abundance to increase in the small intestine with butyrate 
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and SCFA-supplemented TPN infusion, whereas we expect colonic muc2 mRNA abundance to 
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Figure 1.1: Peyer’s patch in the neonatal piglet.  The M cell does not contain the basolateral 
pocket that is characteristic of mature M cells.  The antigen is present at the luminal surface of the 
FAE, and upon M cell engulfment, a dendritic cell recognizes the antigen as a pathogen and 
transports the antigen to the lamina propria in or beyond the SED or to the nearest MLN via the 
afferent lymphatic system. 
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CHAPTER 2 
THE EFFECT OF BUTYRATE-SUPPLEMENTED TOTAL PARENTERAL 
NUTRITION ON muc2 mRNA AND GOBLET CELL CHEMOTYPES IN A SHORT 
BOWEL SYNDROME NEONATAL PIGLET MODEL 
  
ABSTRACT 
Background:  Compromised barrier function and bacterial translocation are common 
complications of short bowel syndrome (SBS) and parenteral nutrition (PN).  Although mucins help 
prevent intestinal bacteria translocation, total mucin production has been shown to decrease during 
PN infusion.  Butyrate administration may be a mucin fortifying strategy as it has been shown to 
increase mucin production in vivo and ex vivo.   
Objective:  We tested the hypothesis that infusion of TPN supplemented with 9 mM butyrate will 
enhance protective goblet cell chemotypes in the small intestine, specifically sulfomucins, that 
enhancement of protective goblet cell chemotypes in the SCFA-supplemented group will be 
observed, since this group also contains 9 mM butyrate, that butyrate-supplemented TPN will have a 
greater effect on the small intestine than the large intestine, while butyrate supplementation at 60 
mM will have a greater effect on the large intestine than the small intestine.  We also hypothesize 
that muc2 mRNA abundance will increase in the small intestine with butyrate and SCFA-
supplemented TPN infusion, whereas colonic muc2 mRNA abundance will increase in the colon 
with 60 mM butyrate administration. 
Methods: Forty-eight hour old piglets underwent 80% proximal jejunuoileal resection and were 
randomized to one of four groups: control total parenteral nutrition (TPN), TPN supplemented 
with 60 mM SCFA (36 mM acetate, 15 mM propionate, and 9 mM butyrate; SCFA), 9 mM butyrate 
(9Bu) or 60 mM butyrate (60Bu).  Animals were further randomized to an acute (12 hour) or chronic 
(72 hour) time point.  muc2 mRNA abundance, total goblet cell number, and total sulfomucin, 
sialomucin, acidomucin, and neutral mucin goblet cell numbers were ascertained. 
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Results:  Sulfomucin chemotypes were increased in the jejunal villi of the 9Bu group compared to 
control (treatment main effect, p=0.047).  Acidomucin chemotypes in ileal crypts were greater in the 
60Bu group than the control group (treatment main effect, p=0.038).  In the colonic crypts, SCFA 
groups tended to have greater acidomucin chemotypes than control at 12h while 60Bu group tended 
to have greater acidomucin chemotypes per depth than control at 72h (p=0.060; Table 2.3).  muc2 
mRNA was increased in jejunal tissues in the 9Bu group compared to control with 270% and 30% 
increases in muc2 mRNA at 12 and 72 hours, respectively (p=0.010).   
Conclusion:  The 9 mM Bu treatment increased protective goblet cell chemotypes and muc2 mRNA 
in the jejunum while 60 mM Bu increased protective goblet cell chemotypes in the ileum and colon.  
The 9Bu treatment was the most effective at upregulating muc2 mRNA abundance and sulfomucin 
chemotypes.  Butyrate-supplemented PN may be a therapeutic strategy for bolstering the epithelial 




Within the first line of defense against invading pathogens—innate immunity—is intestinal 
mucous, the majority of which is secretory gel-forming mucins, predominantly Muc2, a mucous 
protein encoded by the muc2 gene (Gum et al., 1989; Griffiths et al., 1990). Mucins are classified as 
acidomucins or neutral mucins.  Acidomucins have either sulfate or sialic acid residues on their 
carbohydrate moieties and are called sulfomucins and sialomucins, respectively, whereas neutral 
mucins have no such residues (Hansson et al., 1991; Carlstedt et al., 1993).  Sulfomucins and neutral 
mucins confer a more protective effect in the intestine than sialomucins because they are more 
slowly degraded by bacteria, therefore the established continuum of mucin protection is as follows: 
sulfomucins > neutral mucins >>> sialomucins (Fontaine et al., 1996). 
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Several studies confirm the protective nature of sulfomucins (Sakata and von Engelhardt, 
1981; Deplancke et al., 2000; Conour et al., 2002; Dawson et al., 2009).  It has been demonstrated 
that sulfomucins increase in concentration from the duodenum to the colon, mirroring the pattern 
of bacterial concentration from proximal to distal bowel (Sakata and von Engelhardt, 1981; 
Deplancke and Gaskins, 2001; Conour et al., 2002).   Sulfated mucins have been shown to be 
essential in protecting against bacterial translocation (Dawson et al., 2009). 
Muc2 is crucial in preventing bacterial contact with the epithelial lining (Johansson et al., 
2008).  Decreases in mucin abundance or in protective goblet cell chemotypes leave the epithelial 
barrier exposed to bacteria and bacterial products, which can lead to bacterial translocation (Gork et 
al., 1999).  Direct contact of harmful luminal contents to the epithelial lining promotes 
inflammation, which can further impair barrier function (Yang et al., 2002; Yang et al., 2008) and 
increase the risk of bacterial translocation.  Bolstering mucin quality and abundance may improve 
the outcome of SBS patients by preventing bacteria-induced mucosal inflammation and further 
complications such as bacterial translocation.   
Mucin abundance is decreased by PN administration, which is the primary nutritional 
therapy for individuals with intestinal failure (Iiboshi et al., 1994; Bertolo et al., 1998; Law et al., 
2007).  The SCFA butyrate enhances mucin production in vitro and ex vivo (Finnie et al., 1995; 
Willemsen et al., 2003; Hatayama et al., 2007; Burger-van Paassen et al., 2009), but its direct effect 
on mucin chemotype and abundance in vivo and systemically administered as a component of PN has 
not been elucidated.   This study analyzes the effect of parenteral butyrate and SCFA administration 
on both muc2 mRNA abundance and goblet cell chemotypes in a TPN-supported neonatal piglet 
with SBS.  We hypothesized that infusion of TPN supplemented with 9 mM butyrate would 
enhance protective goblet cell chemotypes in the small intestine, specifically sulfomucins.  Similarly, 
we expected enhancement of protective goblet cell chemotypes in the SCFA-supplemented group 
 32
too, since this group also contained 9 mM butyrate.  Further, we hypothesized that butyrate-
supplemented TPN would have a greater effect on the small intestine than the large intestine, while 
butyrate supplementation at 60 mM would have a greater effect on the large intestine than the small 
intestine because the large intestine is more accustomed to SCFA and may need a larger dose to 
confer a benefit.  As such, we expected muc2 mRNA abundance to increase in the small intestine 
with butyrate and SCFA-supplemented TPN infusion, whereas we expected colonic muc2 mRNA 
abundance to increase in the colon with 60 mM butyrate administration. 
 
MATERIALS AND METHODS 
Experimental Design 
Piglets were obtained at 48 hours of age from the Imported Swine Research Laboratory at 
the University of Illinois at Urbana-Champaign.  Piglets underwent superior vena cava cannulation, 
swivel placement and 80% proximal jejunuoileal resection and were then randomized by initial body 
weight (1.77 ± 0.16 kg, n = 120) to one of four groups: control TPN (TPN), TPN supplemented 
with 60 mM SCFA (36 mM acetate, 15 mM propionate, and 9 mM butyrate; SCFA), 9 mM butyrate 
(9Bu) or 60 mM butyrate (60Bu).  Animals were futher randomized to an acute 12 hour (12h) or a 




The surgical protocol was approved by the Laboratory Animal Care Advisory Committee at 
the University of Illinois at Urbana-Champaign.  Aseptic technique and sterile equipment were used 
at all times.  Piglets were anesthetized with isoflurane (98% oxygen, 2% Isoflurane; Baxter 
Pharmaceutical Products, Inc., Deerfield, Illinois).  Betadine (10% povidone-iodine; Purdue 
Frederick Co., Norwalk, Connecticut) and lidocaine (2% lidocaine HCl, 20mg/ml; Abbott 
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Laboratories, North Chicago, Illinois) were applied to the surgical sites prior to jugular 
catheterization, laporotomy, and catheter externalization.  A 3.5 French polyvinyl chloride catheter 
(Bergen-Brunswig, Lack Zurick, Illinois) was inserted into the external jugular vein through a 3-cm 
incision in the right clavicle region.  The catheter was inserted 6-cm into the external jugular into the 
superior vena cava for TPN infusion.  After placement, the catheter was flushed with 5 mL of 
heparinized saline (20 U/ml; Sigma-Aldrich Co., St. Louis, Missouri) and subcutaneously tunneled 
and externalized in the subscapular region.   
All piglets also received an 80% proximal jejunoileal resection, as follows.  A laparotomy was 
performed to the right of the umbilicus and 15-cm of jejunum distal to the ligament of Treitz and 
75-cm of ileum proximal to the ileoceccal junction were measured.  Following vessel stricture, the 
measured small intestine was excised, weighed and measured, and an anastomosis performed to 
reestablish bowel continuity.  The peritoneum, muscularis, and subcutaneous layers were sutured 
separately.  Piglets’ activity levels were monitored during surgical recovery.  Piglets received Naxcel® 
antibiotic (3 mg/kg BW; SmithKline Beeham Corp., Philadelphia, Pennsylvania) prior to surgery and 
during the entire study period.  Piglets also received buprenorphine analgesic (.01 mg/kg BW; Henry 
Schein Inc., Melville, New York) intramuscularly every 12 hours for the first 24 hours post-surgery 
to minimize discomfort. 
 
Animal Care and Housing 
Piglets were fitted with jackets and swivel tethers (Alice King Chatham Medical Arts, 
Hawthorne, California) to protect infusion lines while allowing the piglets to move freely in their 
cages.  Piglets were individually housed in metabolic cages in the Edward R. Madigan laboratory 
animal care facility at the University of Illinois at Urbana-Champaign.  Radiant heaters were placed 
at the top of the cages to maintain temperature of about 34°C. 
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Parenteral Nutrition Solutions 
PN solutions were prepared and sterilized daily in a laminar flow hood.  The solutions 
contained dextrose, amino acids, lipids, and all essential minerals and vitamins (Table 2.1).  SCFA 
and butyrate were added to the PN solutions at the concentrations previously mentioned.  
Volumetric infusion pumps (IMED 980; St. Louis, Missouri) were used to infuse PN.  A stress 
factor or 20% was included in calculating energy and protein needs resulting in an infusion of 307 
Kcal/Kg/d and 15.5 g amino acids/kg/d.  The piglets received nutrition support continuously 
throughout the duration of the study.  Nutrition needs were calculated daily and PN infusions rates 
adjusted accordingly to ensure adequate supply of energy and nutrients for growth and recovery 
from surgery.   
 
Sample Collection 
At euthanasia, the intestines were promptly removed.  Proximal to the ligament of Treitz 
was considered the duodenum.  Distal from this ligament to the anastomosis was considered the 
jejunum, and distal to the anastomosis and proximal to the ileoceccal valve was considered the 
ileum.  The colon was removed as well.  All segments were flushed with ice-cold saline and samples 
from each segment were fixed in 10% buffered formalin.  Formalin-fixed tissue was dehydrated in 
ethanol and infiltrated and embedded in paraffin wax.  Blocks of tissue were sectioned to 
approximately 5 µm thickness at the Veterinary Medicine Center for Microscopic Imaging and 
sections were placed on polylysine slides for optimal adhesion during staining procedures. 
 
Measurement of muc2 RNA 
Total cellular RNA was isolated from jejunal, ileal, and colonic samples using the guanidium 
isothiocyanate phenolchloroform method of Chomczynski (1993) and as previously described in our 
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lab (Bartholome et al., 2004).  RNA concentration and purity after isolation were determined using a 
Thermo Scientific NanoDrop 2000 (Thermo Scientific, Wilmington, DE).  RNA quality was 
determined by running all samples through ethidium bromide RNA gel electrophoresis and 
examining under UV illumination using a Fotodyne Incorporated 3-3100 UV light box (Fotodyne 
Incorporated, Hartland, WI).  In addition, 12 samples with varying 18S and 28S band intensities in 
gel electrophorosis were chosen for analysis in an Agilent 2100 bioanalyzer (Agilent Technologies, 
Santa Clara, CA) at the W.M. Keck Center for Comparative and Functional Genomics (University of 
Illinois at Urbana-Champaign, Urbana, IL) to further ascertain RNA integrity.  The sample with the 
weakest 18S and 28S band under UV illumination after RNA gel electrophoresis produced a RNA 
integrity number (RIN) of 7.30 in the Agilent 2100 bioanalyzer.  An RIN number is assigned by 
Agilent Technologies’ bioanlyzer software and is a representation of the entire electrophoretic trace 
of an RNA sample including degradation products.  An RIN of greater than 7 is recommended for 
optimal rt-PCR (real time-polymerase chain reaction) results.  Thus, all samples were of high quality 
and ideal for rtPCR.   
Reverse transcription was carried out in a Gene Mate® Genius thermocycler (ISC 
Biosexpress, Kaysville, Utah) as a 20 µL total volume containing 5µg RNA reconstituted in 10 µL 
DEPC water, 1 µL random primer, 1 µL dNTP, 4 µL 5x First-Strand Buffer, 2 µL 0.1 M DTT, 1 µL 
RNaseOut, and 1 µL SuperScript II Reverse Transcriptase.  All of these reagents were obtained 
from Invitrogen Corporation.  rt-PCR consisted of a total reaction volume of 10 µL containing 2 µL 
DEPC water, 2 µL cDNA template, 5 µL of TaqMan® Universal PCR Master Mix, 0.5 µL 
eukaryotic 18S rRNA endogenous control primer and probe 20x (Applied Biosystems, Carlsbad, 
CA), .5 µL Muc2 Custom Made Taqman® Gene Expression Assays PCR primer and probe 
(Applied Biosystems, Foster City, CA).  rt-PCR was completed using a Taqman ABI 7900 real time 
PCR machine (Applied Biosystems, Carlsbad, CA).   
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The oligonucleotide primers specific for Muc2 cDNA detection were made by Applied 
Biosystems Custom Made Taqman® Gene Expression Assays.  The custom probe was designed 
using the National Center for Biotechnology Information (NCBI) nucleotide and protein databases 
and Primer Express 2.0 (Applied Biosystems, Carlsbad, CA).  Because pig DNA for muc2 has not 
yet been elucidated, a search was completed for mouse muc2 mRNA through the nucleotide 
database in NCBI.  Gi accession number 149258274 was chosen because it did not contain long 
segments of repeated codons.  Because mucins commonly have similar protein backbones, especially 
in the center of the molecule, choosing a gene sequence with long segments of repeated codons 
would decrease specificity of the designed primer.  A nucleotide blast was then completed 
comparing this chosen gene against sus scrofa expressed sequence tags (ESTs) with a low complexity 
filter to mask repeat regions.  An 81% identity was found with EST: BX671371 which was then 
blasted against refseq RNA to establish if this EST matches muc2 mRNA already elucidated for 
other species.  A significant alignment of 88% identity was found with NM 002457 or Homo sapiens 
muc2 mRNA.  Then a blastx—protein comparison—of EST BX671371 against non-redundant 
protein sequences was performed resulting in 25 matches of significant alignment with elucidated 
muc2 proteins.  The first 8 matches were 85%-87% similar to EST BX671371, with the 15% 
difference likely due to species differences in mucin proteins.  Accession numbers CAD54416 
(Muc2 protein Mus muscularis-922 amino acids) and AAA59861.1 (Muc2 protein Homo sapiens-131 
amino acids) were blasted against each other with only an 82% alignment, demonstrating the 
interspecies variation of mucin proteins.  BX671371 was entered into Primer Express 2.0 software, 
with temperature, cytosine and guanine content, and primer length at default settings, and the primer 
set with lowest penalty was chosen for custom primer and probe design.  The resulting primer set 
requested from Applied Biosystems is as follows: 
Forward: 5’ – TCCAAGCCTCTCCCTGCAT – 3’ 
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Reverse: 5’ – ACAGCCACCAGGTCTCATTCTC – 3’ 
Probe: 5’ – CAGACTTCGATCCTCCCA – 3’ 
 The rt-PCR product of pooled cDNA of all samples were run on a 1.8% agarose gel with a 
50 base pair DNA ladder (New England Biolabs, Ipswich, MA) and visualized under UV 
illumination on a Molecular Imager® ChemiDoc™ XRS with Quantity One 4.6.3 software (Bio-Rad 
Laboratories, Hercules, CA) to determine the length of the amplicon to verify amplification of the 
target.  One band was present for 18S mRNA while no band was seen for muc2 (Figure 2.1).   
 
Measurement of Mucin Protein: Acidic versus Neutral Mucins 
Samples used for goblet cell chemotype counting were formalin-fixed, sliced to 5 µm 
thickness and placed on polylysine slides.  Samples were stained with periodic acid alcian blue 
(PASAB) carbohydrate stain technique (Mowry, 1956; Carson, 1990).  Sections were deparaffinized, 
stained for 5 minutes with alcian blue, rinsed for 5 minutes in running tap water and 5 minutes in 
ddH20.  They were then incubated for 10 minutes in 1.0% periodic acid, and rinsed again for 5 
minutes in running tap water and ddH20, sequentially.  A 10-minute incubation in Schiff’s reagent 
was conducted, followed by another sequential rinse of tap water, then ddH20.  Lastly, slides were 
counterstained with Harris’s hematoxylin with acetic acid for 15 seconds, rinsed in running tap water 
for 10 minutes, dehydrated, and cover-slipped.  PASAB stain colors neutral mucins pink and acidic 
mucins blue (Figure 2.2).  Another scientist blinded the histologist to the sample origin.  Up to 10 
well-oriented and intact villi and crypt units were identified in each sample, length and depth 
measured, and goblet cells counted.  Goblet cells were counted, then categorized to one of the 
following 5 groups: 1.) 100% acidomucin; 2.) 75% acidomucin and 25% neutral mucin; 3.) 50% 
acidomucin and 50% neutral mucin; 4.) 25% acidomucin and 75% neutral mucin, and; 5.) 100% 
neutral mucin.  The mixed goblet cells (Figure 2.3) were partitioned into the group that most 
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closely matched its composition.  In addition, to obtain solely acidomucin and neutral mucin values 
of all goblet cells, calculations of the mixed goblet cells—those containing both acidomucin and 
neutral mucin components—were completed to distribute acidomucin and neutral mucin 
components into either the 100% acidomucin chemotype or 100% neutral mucin chemotype 
groups.  Images were obtained using a Zeiss Axioskop 40 microscope and a Zeiss AxioCam MRc 5 
camera (Carl Zeiss IMT Corporation, Maple Grove, MN).  Length and depth measurements of 
crypts and villi were obtained using AxiovisionLE Software (Release 4.7.2, Carl Zeiss).  Images for 
publication were obtained using an Olympus BX51 microscope, an Olympus DP70 digital camera 
and DP Manager software (Olympus America Inc., Center Valley, PA).   
 
Measurement of Sulfomucin versus Sialomucin Goblet Cell Chemotypes 
Samples used for goblet cell chemotype counting were formalin-fixed, sliced to 5 µm 
thickness and placed on polylysine slides.  Samples were stained with high iron diamine alcian blue 
(HIDAB) carbohydrate stain technique, as previously described (Spicer, 1965; Spicer et al., 1965; 
Carson, 1990), except incubation in high iron diamine solution was limited to 16 hours rather than 
18 hours to reduce non-specific staining.  Following high iron diamine stain, slides were washed in 
running tap water for 5 minutes and stained with alcian blue (pH 2.5) for 5 minutes, washed in 
running tap water for 2-3 minutes, counterstained with Nuclear Fast Red (Sigma Aldrich, St. Louis, 
MO) for 1-2 minutes, washed in running tap water for 5 minutes, dehydrated, and cover-slipped.  
HIDAB stain colors sulfated mucins brown and sialated mucins blue (Figure 2.4).  Another 
scientist blinded the histologist to the sample origin.  Up to 10 well-oriented and intact villi and 
crypt units were identified in each sample, length and depth measured, and goblet cells counted.  
Goblet cells were counted in one of the 5 following groups: 1.) 100% sulfomucin; 2.) 75% 
sulfomucin and 25% sialomucin; 3.) 50% sulfomucin and 50% sialomucin; 4.) 25% sulfomucin and 
 39
75% sialomucin; and 5.) 100% sialomucin.  These mixed goblet cells (Figure 2.5) were partitioned 
into the group that most closely matched its composition.  Calculations were carried out and imaged 
captured as described in the previous section. 
 
Statistical Analysis 
Data were analyzed using the mixed model in SAS statistical software (version 9.1; SAS 
Institute, Cary, NC).  Analysis was completed using analysis of variance (ANOVA) for a split-plot 
design.  Sources of variation include litter (block), time (main plot), and treatment (subplot).  
Residuals were output from the mixed model and the Shapiro-Wilk test was used to test for 
normality.  Spearman correlation tests were performed on the residuals to test for homogeneity.  
Log or reciprocal transformations were performed for any data that was not normal or had unequal 
distribution of residuals.  After p-values were obtained, data was retransformed to acquire the 
correct mean estimate and the standard error of retransformed data is presented as an average of 
standard error (SE) values calculated from both the upper and lower retransformed confidence 
intervals of group means.  If the main effects for time or treatment, or the interaction of 
time*treatment were significant, the following post hoc comparisons were conducted: control versus 
9Bu at 12h, control versus 60Bu at 12h, control versus SCFA at 12h, control versus 9Bu at 72h, 
control versus 60Bu at 72h, and control versus SCFA at 72h.  These comparisons were completed 
for rt-PCR results, total goblet cell number, sulfomucin versus sialomucin chemotype abundance, 
and acidomucins versus neutral mucins chemotype abundance.  Significant data are identified as p≤ 
0.050 and trends identified by p≤ 0.100.  Data were analyzed as one-tailed t-tests given the 








Body and Organ Weights 
As previously reported by our research group, piglet body weight did not differ between 
control piglets and those receiving SCFA and butyrate supplementation at any point during the 
study (Bartholome et al., 2004).  In addition, organ weights did not differ between groups at the 
conclusion of the study (Bartholome et al., 2004). 
 
Total Goblet Cell Number 
 
In the jejunal villi, 12h total goblet cell number per height tended to be greater than 72h total 
goblet cell number (time main effect, p=0.074; Table 2.2).  In the ileal crypts, 12h goblet cell 
number per depth was significantly greater than that at 72h (time main effect, p=0.0004; Table 2.2).  
No significance was noted in the colon (Table 2.2).   
 
Acidomucin and Neutral Mucin Goblet Cell Chemotypes  
Within the jejunal and ileal crypts, 12h neutral chemotypes per crypt depth (in µm) were 
significantly greater than at 72h (p=0.005, p=0.012, respectively; Table 2.3).  Within the ileal crypt, 
12h acidomucin chemotypes per depth were also greater at 12h than at 72h (p=0.0003).  Also within 
the ileal crypt, acidomucin chemotypes per depth were greater in the 60Bu group than the control 
group (treatment main effect, p=0.038; Figure 2.6).  In the colonic crypts, SCFA groups tended to 
have greater acidomucin chemotypes per depth than control at 12h while 60Bu group tended to 
have greater acidomucin chemotypes per depth than control at 72h (p=0.060; Table 2.3). 
Within the ileal villi, SCFA and 60Bu acidomucin chemotypes per villus height (in µm) were 
greater than control at 12h; however, these differences were not sustained at 72h (p=0.031; Table 
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2.4; Figure 2.7).  No significant differences or trends were noted in the jejunum for either neutral 
mucin chemotypes or acidomucin chemotypes per height (Table 2.4).   
 
Sulfomucin and Sialomucin Goblet Cell Chemotypes 
 Within the ileal crypts, sialomucin chemotypes per depth tended to be greater at 12h than at 
72h (time main effect, p=0.054; Table 2.5).  Within the colonic crypts, control sialomucin 
chemotypes per depth were greater than 9Bu, 60Bu, and SCFA at 72h (p=0.039; Table 2.5; Figure 
2.8).  No differences were noted in the jejunal crypts. 
 Within the jejunal villi, 9Bu had greater sulfomucin chemotypes per height than control 
(treatment main effect, p=0.047; Table 2.6; Figure 2.9).  Also within the jejunal villi, sialomucin 
chemotypes per height tended to be greater at 72h than at 12h (p=0.058; Table 2.6).  Within the 
ileal villi, control groups had greater sialomucin chemotypes than SCFA groups at 12h; however, this 
difference was not seen at 72h (p=0.0004; Table 2.6). 
 
Muc2 mRNA Abundance 
 
 Within the jejunum, muc2 mRNA was greater in the 9Bu group than the control group 
(treatment main effect, p=0.010; Table 2.7; Figure 2.10).  Within the ileum, muc2 mRNA was 
greater at 72h than at 12h (p=0.017; Table 2.7).  No significance was noted in the colon. 
 
DISCUSSION 
The goal of this study was to investigate the effect of butyrate and SCFA administration via 
parenteral nutrition on mucin production in the jejunum, ileum, and colon.  Our study revealed 
significant increases at the transcriptional level of mucin production and significant increases in 
protective goblet cell chemotypes upon butyrate supplementation.  This study used a parenterally-
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supported SBS neonatal piglet model that is recognized as an ideal model for gastrointestinal disease 
in the human infant for two reasons.  First, the timing of gastrointestinal maturation is quicker than 
humans, but clusters in a similar ratio, meaning the pig is a close reflection of human maturation 
sequences but matures in much less time, naturally lending itself to the research setting (Sangild, 
2006).  Further, piglets have shown similar intestinal adaptation to humans post-resection 
(Heemskerk et al., 1999).  Thus, due to the interspecies similarities in the gastrointestinal tract, the 
piglet’s mucin responses to resection, PN, and butyrate administration will likely be similar to 
humans’ response.   
In this study, the number of acidomucin goblet cell chemotypes per crypt were nearly double 
that of the neutral mucin chemotypes in the colon of the control piglets which mirrors the natural 
state of mucin ratios seen in neonatal life in humans (Filipe et al., 1989; Deplancke and Gaskins, 
2001), further demonstrating the validity of the piglet model for study of goblet cell development 
and chemotypes.  
Gel electrophoresis of pooled cDNA samples produced a faint 18S band; however no muc2 
band was present. The 18S band was estimated to be 18 ng while the lowest amount present in the 
DNA ladder was approximately 27 ng.  Even though 40 uL of rt-PCR amplicon was injected into 
the sample well, the 18S band was still faint.  rt-PCR demonstrated by CT counts that 18S was 
exponentially greater in quantity than muc2.  Thus, we believe that muc2 is at a concentration that is 
high enough to be detected by rt-PCR, but not high enough to be visible on a gel.  However, rt-PCR 
verified amplification of muc2.  Additionally, Taqman primer and probe sets are highly sensitive and 
specific, and NCBI blasts confirmed that the primer and probe sets have significant alignment with 
Sus scrofa ESTs and muc2 mRNA of other species demonstrating that the primer and probe sets 
would amplify Sus scrofa muc2.   
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Sulfomucin goblet cell chemotypes increased within the jejunal villi of the 9Bu group.  As 
previously mentioned, sulfomucins are the most protective against bacterial degradation, with 40% 
degraded at 4 hours after bacterial inoculation, followed by neutral mucins with 55% degraded at 4 
hours post-inoculation, and followed lastly by sialomucins which are 90% degraded at 1 hour and 
almost completely degraded at 4 hours (Fontaine et al., 1998).  With a 37.3% increase of villus 
sulfomucin chemotypes at 12h and a 10.7% increase at 72h, the 9Bu group likely has an improved 
protective barrier against bacteria than the control group.  The increase in sulfomucin chemotype in 
the 9Bu group was mirrored by significant jejunal muc2 mRNA increases in the 9Bu group.  A 270% 
increase in muc2 mRNA was noted at 12h and a 30% increase was observed at 72h.  Enhancement 
by 9Bu at the transcriptional level and enhancement of protective goblet cell chemotypes were 
greater at the acute time point (12h) than the chronic time point (72h), suggesting that butyrate 
administration may be more beneficial for the jejunum immediately after small bowel resection.  
Because 9Bu had positive effects but SCFA did not (SCFA is 60mM total concentration SCFA with 
9mM butyrate), 60mM total concentration may be inhibitory in the jejunum.  This will be discussed 
in more depth shortly. 
The distal small bowel did not show any significant improvements versus control with 9Bu 
treatment.  In the ileum, 60Bu significantly enhanced crypt acidomucin chemotypes compared to 
control (treatment main effect).  There was a 16.4% increase at 12h and a 32.6% increase at 72h.  In 
addition, 60Bu and SCFA enhanced villus acidomucin chemotypes at 12h by 75.5% and 44.7%, 
respectively.  These data indicate that butyrate supplementation of 60Bu is most beneficial for the 
ileum and that benefits are seen at both acute and chronic time points.  They also indicate that since 
60Bu and SCFA—both 60mM treatments, but differing butyrate concentrations—had positive 
effects, that concentration of short chain fatty acids, rather than type of short chain fatty acid may 
be the mechanism by which the mucin is enhanced in the ileum.  Conversely, since 60Bu produced a 
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greater increase in acidomucin chemotypes than the SCFA group, one could also argue that butyrate 
was the source of mucin enhancement, and that the greater concentration of butyrate may have 
increased the benefit.   
Colonic goblet cell abundance and chemotype was not altered by the 9Bu treatment.  
However, SCFA and 60Bu tended to increase acidomucin chemotypes at 12h and at 72h, 
respectively.  This again suggests that the distal bowel may need greater butyrate concentrations than 
the jejunum to confer benefits. 
There are a couple possibilities for why the jejunum may have responded positively to 9Bu 
while the ileum and colon responded positively to 60Bu.  The 9mM dosage of butyrate administered 
to the piglets averaged 2.21mM/hour for the average piglet weight, while the 60mM butyrate dosage 
averaged 14.9mM/hour.  As discussed previously, 1-2 mM of butyrate has been shown to be 
beneficial upon luminal administration, while 5-15 mM has been shown to be detrimental (Barcelo et 
al., 2000; Willemsen et al., 2003; Hatayama et al., 2007; Burger-van Paassen et al., 2009).  No studies 
have been conducted on an upper limit of butyrate administered parenterally; however, it seems 
there may be an upper limit of butyrate tolerance for the jejunum, at least.  Because bacterial 
concentrations increase from proximal to distal bowel, the ileum is accustomed to greater SCFA 
concentration than the jejunum.  Therefore, it is conceivable that a higher concentration of butyrate 
is needed—even when administered parenterally—to stimulate beneficial effects in the ileum versus 
the jejunum.  Furthermore, because the jejunum is exposed to less fermentative products such as 
butyrate, 60mM butyrate may be beyond the tolerable level of short chain fatty acids for the 
jejunum.  As previously shown, plasma concentrations of SCFA are not elevated in this piglet model 
with administration of 60 mM SCFA, 9 mM butyrate, and 60 mM butyrate (Bartholome et al., 2004), 
indicating that either the upper limit was not reached with these dosages, or an upper limit cannot be 
defined by remaining plasma concentrations.  Rather, upper limits may need to be defined by 
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measured structural and functional indices of the intestine such as protective goblet cell chemotype 
abundance. 
Sialomucins have been shown to be less protective than sulfomucins and neutral mucins 
(Fontaine et al., 1998).  In this study, control groups had greater sialomucin chemotypes than the 
SCFA group at 12h in the ileum and control groups in the colon had greater sialomucin chemotypes 
than all treatment groups at 72h.  Sialomucin chemotypes only comprise 2% of the total colonic 
goblet cells in these tissues, so although the decrease in sialomucin chemotypes was seen, it was a 
negligible decrease as sialomucins are such a minor component of large intestinal mucin.  Further, 
humans have an even greater ratio of sulfomucins/sialomucins than piglets (Deplancke and Gaskins, 
2001).  Due to sialomucins not being as protective as other mucins, sialomucin chemotypes 
composing a small percentage of total colonic goblet cells, and the greater sulfomucin/sialomucin 
ratio in humans, decreases in sialomucins by SCFA and butyrate administration are statistically but 
not clinically significant.  Although neither a decrease nor an increase in sialomucins is clinically 
significant, additional mucins no matter how easily degraded could only be beneficial as long as there 
is no concomitant decrease in sulfomucins or neutral mucins.  A significant increase in sialomucin 
chemotypes was noted in the jejunal villus with 9Bu, which could only be a beneficial adaptation.   
Significant time differences were noted in that jejunal crypt neutral mucin chemotypes and 
ileal crypt neutral mucin, acidomucin and sialomucin chemotypes were greater at 12h than at 72h 
(time main effect).  Because there were no treatment differences, the apparent decrease in goblet cell 
chemotypes from 12-72h were not due to SCFA or butyrate administration.  Rather, there was a 
trend for a decrease in jejunal crypt total goblet cells and a significant decrease in ileal crypt total 
goblet cells, showing that this is likely a natural physiological change seen in piglets recovering from 
massive bowel resection.  The decrease of total goblet cell number at 72h can be explained by the 
effect parenteral nutrition has on mucin production and other indices of intestinal functioning 
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previously mentioned.  It may be that the upregulation in mucins provided by butyrate treatment or 
adaptation cannot outweigh the increasingly damaging effects that PN administration has on 
mucosal function and morphology over time.  As we have previously reported, this piglet model 
experiences an increased rate of crypt cell proliferation with SCFA and butyrate administration 
compared to control piglets; however, all piglets have a decreased rate of crypt cell proliferation at 
72h compared to 12h demonstrating that administration of SCFA and butyrate may not be able to 
overcome the negative effects of PN administration over time (Bartholome et al., 2004).   
The regulation of mucin expression has not been established in this study or in other 
literature.  In this study, ileal muc2 was greater at 72h than at 12h, but ileal crypt goblet cells were 
greater at 12h than at 72h with no significant differences noted in the ileal villi.  This suggests that 
goblet cell chemotype development is regulated at the translational level.  However, jejunal 
regulation of mucin expression appears to be transcriptionally regulated.  muc2 mRNA abundance in 
the jejunum was increased by 9Bu treatment with a concomitant increase in jejunal sulfomucin and 
sialomucin chemotypes, indicating that an increase in mucin gene transcription may lead to an 
increase in mucin protein translation.  Further study needs to be conducted to clarify the 
mechanism(s) of mucin and goblet cell chemotype regulation and how these methods may vary 
along the length of the intestinal tract. 
In summary, with adequate nutritional provision, upregulations of protective goblet cell 
chemotypes and muc2 expression occurred with butyrate and SCFA administration.  The 9Bu 
treatment produced the best improvement of the jejunal mucin profile, while SCFA and 60Bu 
treatments improved the ileal mucin profile.  Because of the discrepancy in benefit between 
treatments, the ideal treatment may depend on the etiology of intestinal failure and resulting bowel 
resection.  A larger remaining jejunum than ileum post-resection may have greater benefit from the 
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9Bu treatment while a greater remaining ileum versus jejunum post-resection may receive greater 
benefit from the SCFA or 60Bu treatments.   
In conclusion, SCFA-supplemented TPN enhances protective goblet cell chemotypes in the 
neonatal intestine of a SBS model piglet, and butyrate-supplemented TPN enhances both muc2 
mRNA and protective goblet cell chemotypes in the neonatal intestine of a SBS model piglet.  
Therefore, supplementation of TPN with SCFA or butyrate may benefit infants with SBS by 
increasing protective goblet cell chemotypes and muc2 expression, potentially decreasing PN-
associated complications such as bacterial translocation. 
 
Table 2.1: Composition of parenteral nutrient solutions 
Ingredients TPN1    TPN + 9Bu2 TPN + 60Bu2 TPN + SCFA2
  Dextrose3,4 (ml/L) 235.3 231.9 216.2 224.2 
Amino acids4,5 (ml/L) 594.0 594.0 594.0 594.0 
Lipids4,6 (ml/L) 133.3 133.3 133.3 133.3 
Acetic acid7 (mmol/L) __ __ __ 36.0 
Propionic acid7 (mmol/L) __ __ __ 15.0 
n-Butyric acid7 (mmol/L) __ 9.0 60.0 9.0 
MTE-68,9 (µl/L) 100.0 100.0 100.0 100.0 
Iron dextran10 (µl/L) 111.0 111.0 111.0 111.0 
Calcium gluconate9,11 (µl/L) 2.2 2.2 2.2 2.2 
Vitamin A + E + D12 (µl/L) 23.5 23.5 23.5 23.5 
Vitamin K13 (µl/L) 20.0 20.0 20.0 20.0 
Vitamin C14,15 (µl/L) 320.0 320.0 320.0 320.0 
Vitamin B complex14,16 
(µl/L) 
200.0 200.0 200.0 200.0 
Folic acid17 (µl/L) 28.0 28.0 28.0 28.0 
Biotin7,18 (µl/L) 20.0 20.0 20.0 20.0 
Sterile water (ml/L) 34.4 37.0 48.2 41.4 
 
1TPN represents a standard total parenteral nutrient solution providing; energy, 1 Kcal/ml; 
carbohydrate, 100mg/ml; amino acids 50.5 mg/ml; lipid 40 mg/ml. 
2TPN + 9Bu, TPN + 60Bu, and TPN + SCFA represent standard total parenteral nutrient solution 
plus the short-chain fatty acids listed. 
350% dextrose (50 g dextrose/100 ml). 
4Baxter Healthcare Corporation, Deerfield, Illinois. 
58.5% Travasol®; (leucine 529 mg, phenylalanine 526 mg, lysine 492 mg, methionine 492 mg, 
isoleucine 406 mg, valine 390 mg, histidine 372 mg, threonine 356 mg, tryptophan 152 mg, alanine 
176 mg, glycine 176 mg, arginine 880 mg, proline 356 mg, tyrosine 34 mg, Na+ 70 mM, K+ 60 mM, 
Mg2+ 5 mM, Cl- 70 mM, PO4- 30 mM, acetate 130 mM); Baxter Healthcare Corporation. 
630% Intralipid® (soybean oil 30g phospholipids 1.2g glycerine 1.7g)/100 ml; Baxter Healthcare 
Corporation. 
7Sigma-Aldrich Co., St. Louis, Missouri. 
8Contains: chromium .3 µmol/L; copper 25.2 µmol/L; iodine 1.9 µmol/L; manganese 21.6 µmol/L; 
selenium 1.0 µmol/L; zinc 492 µmol/L. 
9Fujisawa USA, Inc. Deerfield, Illinois. 
10Contains; elemental iron 100mg/ml; Rhone Merieux, Inc., Athens, Georgia. 
11Contains: calcium 2.14g/100 ml. 
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Table 2.1, continued 
 
12Vital E® -A+D Durvet; Contains: vitamin A 2331 IU; vitamin E 233 IU; vitamin D 7 IU; 
Boehringer Ingelheim Animal Health, Inc., St. Joseph, Missouri. 
13Contains; phytonadione 10 mg/ml; K-Ject Vetus Animal Health; Burns Veterinary Supply Inc., 
Rockville Centre, New York. 
14Vedco Inc., St. Joseph, Missouri. 
15Contains: sodium ascorbate 250 mg/ml. 
16Contains: thiamin hydrochloride (B1) 12.5 mg/ml; niacinamide (B3) 12.5 mg/ml; pyridoxine 
hydrochloride (B6); d-panthenol 5 mg/ml; riboflavin (B2; as riboflavin 5’ phosphate sodium) 2 
mg/ml; cyanocobalamin (B12) 5 µg/ml. 
17Contains: folic acid 5 mg/ml; American Pharmaceutical Partners, Inc., Los Angeles, California.  






 Table 2.2: Effect of short-chain fatty acid-supplemented total parenteral nutrition on total villus and crypt goblet cells following massive 
small bowel resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
         
VILLUS         
         
Jejunum         
12h 0.038 ± 0.006 0.042 ± 0.007 0.030 ± 0.004 0.036 ± 0.006 
72h 0.036 ± 0.005 0.034 ± 0.005 0.039 ± 0.006 0.033 ± 0.005 
         
Ileum         
12h 0.025 ± 0.004 0.021 ± 0.006 0.021 ± 0.007 0.041 ± 0.007 
72h 0.029 ± 0.006 0.036 ± 0.006 0.025 ± 0.005 0.027 ± 0.005 
         
CRYPT         
         
Jejunum3         
12h 0.093 ± 0.007 0.095 ± 0.007 0.085 ± 0.007 0.101 ± 0.010 
72h 0.076 ± 0.008 0.082 ± 0.007 0.088 ± 0.008 0.091 ± 0.007 
         
Ileum4         
12h 0.096 ± 0.009 0.103 ± .00802 0.109 ± 0.008 0.106 ± 0.008 
72h 0.073 ± 0.009 0.080 ± 0.008 0.094 ± 0.008 0.081 ± 0.008 
         
Colon         
12h 0.126 ± 0.011 0.113 ± 0.011 0.120 ± 0.012 0.137 ± 0.013 
72h 0.116 ± 0.013 0.121 ± 0.012 0.133 ± 0.015 0.123 ± 0.013 
         
 
1 All values are mean ± SEM expressed as relative goblet cell number per depth and is adjusted to include neutral and acidic fractions  
of mixed cells.  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in SAS 9.1 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, 12h tended to be greater than 72h (time main effect, p=0.074).   
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Table 2.2, continued 
 
4 Within this dependent variable, 12h is greater than 72h (time main effect, p=0.0004). 
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Table 2.3: Effect of short-chain fatty acid-supplemented total parenteral nutrition on neutral and acidic goblet cell chemotypes  
following massive small bowel resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
         
NEUTRAL         
         
Jejunum3         
12h 0.0383 ± 0.0043 0.0377 ± 0.0043 0.0284 ± 0.0043 0.0405 ± 0.0062 
72h 0.0243 ± 0.0054 0.0235 ± 0.0043 0.0264 ± 0.0048 0.0247 ± 0.0045 
         
Ileum4         
12h 0.0285 ± 0.0039 0.0274 ± 0.0034 0.0309 ± 0.0039 0.0271 ± 0.0037 
72h 0.0230 ± 0.0028 0.0233 ± 0.0029 0.0258 ± 0.0033 0.0231 ± 0.0029 
         
Colon         
12h 0.0479 ± 0.0055 0.0380 ± 0.0055 0.0421 ± 0.0061 0.0410 ± 0.0070 
72h 0.0356 ± 0.0068 0.0358 ± 0.0060 0.0296 ± 0.0080 0.0453 ± 0.0069 
         
ACIDIC         
         
Jejunum         
12h 0.0012 ± 0.0003 0.0013 ± 0.0003 0.0013 ± 0.0003 0.0015 ± 0.0006 
72h 0.0010 ± 0.0003 0.0013 ± 0.0003 0.0011 ± 0.0003 0.0017 ± 0.0005 
         
Ileum5,6         
12h 0.0669 ± 0.0056 0.0746 ± 0.0051 0.0779 ± 0.0051 0.0691 ± 0.0056 
72h 0.0516 ± 0.0056 0.0543 ± 0.0051 0.0684 ± 0.0051 0.0571 ± 0.0051 
         
Colon7         
12h 0.0779 ± 0.0070 0.0754 ± 0.0070 0.0779 ± 0.0078 0.0961 ± 0.0088 
72h 0.0802 ± 0.0087 0.0856 ± 0.0078 0.1040 ± 0.0102 0.0785 ± 0.0090 




Table 2.3, continued 
 
1 All values are mean ± SEM expressed as relative goblet cell number per depth and is adjusted to include neutral and acidic fractions  
of mixed cells.  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in SAS 9.1 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, 12h was greater than 72h (time main effect, p=0.005). 
4 Within this dependent variable, 12h was greater than 72h (time main effect, p=0.012). 
5 Within this dependent variable, 12h was greater than 72h (time main effect, p=0.0003). 
6 Within this dependent variable, 60Bu was greater than control (treatment main effect, p=0.038). 






















Table 2.4: Effect of short-chain fatty acid-supplemented total parenteral nutrition on villus neutral mucin and acidomucin chemotypes  
per villus height following massive small bowel resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
 Mean  Mean  Mean  Mean  
NEUTRAL         
         
Jej  unum         
12h 0.01861 ± 0.00451 0.02178 ± 0.00594 0.01210 ± 0.00266 0.01490 ± 0.00407 
72h 0.01370 ± 0.00301 0.01406 ± 0.00309 0.01425 ± 0.00313 0.01294 ± 0.00284 
         
Ileum         
12h 0.00006 ± 0.00003 0.00009 ± 0.00005 0.00006 ± 0.00004 0.00011 ± 0.00006 
72h 0.00003 ± 0.00002 0.00006 ± 0.00003 0.00006 ± 0.00004 0.00004 ± 0.00003 
         
ACIDIC         
         
Jej  unum         
12h 0.01862 ± 0.00318 0.01821 ± 0.00349 0.01730 ± 0.00269 0.02037 ± 0.00390 
72h 0.01994 ± 0.00310 0.01885 ± 0.00293 0.01929 ± 0.00299  0.01885 ± 0.00293 
         
Ileum3         
12h 0.00930 ± 0.00199 0.01346 ± 0.00320 0.01632 ± 0.00441 0.02161 ± 0.00462 
72h 0.01622 ± 0.00387 0.02027 ± 0.00437 0.01032 ± 0.00280 0.01533 ± 0.00376 
         
 
1 All values are mean ± SEM expressed as relative goblet cell number per depth and is adjusted to include neutral and acidic fractions  
of mixed cells.  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in SAS 9.1 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, SCFA and 60Bu were greater than control at 12h (p=0.031); however these differences were not 
sustained at 72h. 
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Table 2.5: Effect of short-chain fatty acid-supplemented total parenteral nutrition on crypt sulfomucin and sialomucin chemotypes  
per crypt depth following massive small bowel resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
         
SULFATED         
         
Jej  unum         
12h 0.06551 ± 0.01052 0.06391 ± 0.01052 0.05886 ± 0.00969 0.07864 ±  0.00969 
72h 0.06376 ± 0.00963 0.06069 ± 0.00963 0.06384 ± 0.00958 0.05311 ± 0.01003 
         
I  leum         
12h 0.04090 ± 0.00991 0.03207 ± 0.00738 0.04613 ± 0.01605 0.04947 ± 0.01137 
72h 0.04394 ± 0.01014 0.04626 ± 0.00995 0.04510 ± 0.00960 0.05370 ± 0.01213 
         
Colon         
12h 0.13490 ± 0.00945 0.13690 ± 0.01059 .13130 ± 0.01015 0.13350 ± 0.01015 
72h 0.13470 ± 0.01189 0.13700 ± 0.01048 .12280 ± 0.01409 0.13180 ± 0.01074 
         
SIALYLATED         
         
Jej  unum         
12h 0.00008 ± 0.00017 0.00027 ± 0.00035 0.00045 ± 0.00048 0.00010 ± 0.00018 
72h 0.00004 ± 0.00011 0.00013 ± 0.00019 0.00001 ± 0.00009 0.00019 ± 0.00026 
         
Ileum3         
12h 0.05824 ± 0.00844 0.06547 ± 0.00844 0.05856 ± 0.00895 0.04849 ± 0.00844 
72h 0.04580 ± 0.00799 0.04242 ± 0.00807 0.03523 ± 0.00867 0.04545 ± 0.00845 
         
Colon4         
12h 0.00101 ± 0.00057 0.00051 ± 0.00062 0.00114 ± 0.00062 0.00084 ± 0.00062 
72h 0.00304 ± 0.00070 0.00082 ± 0.00062 0.00004 ± 0.00081 0.00004 ± 0.00065 




Table 2.5, continued 
 
1 All values are mean ± SEM expressed as relative goblet cell number per depth and is adjusted to include sulfated and sialylated  
fractions of mixed cells.  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in SAS 9.1 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, 12h tended to be greater than 72h (time main effect, p=0.054). 
4 Within this dependent variable, control was greater than 9Bu, 60Bu, and SCFA at 72h (p=0.039). 
 
 
Table 2.6: Effect of short-chain fatty acid-supplemented total parenteral nutrition on villus sulfomucin and sialomucin chemotypes  
per villus height following massive small bowel resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
         
SULFATED         
         
Jejunum3         
12h 0.0343 ± 0.0038 0.0471 ± 0.0038 0.0395 ± 0.0034 0.0371 ± 0.0034 
72h 0.0364 ± 0.0034  0.0403 ± 0.0034 0.0340 ± 0.0038 0.0351 ± 0.0035 
         
Ileum         
12h 0.0321 ± 0.0043 0.0317 ± 0.0038 0.0383 ± 0.0057 0.0343 ± 0.0045 
72h 0.0280 ± 0.0031 0.0315 ± 0.0037 0.0290 ± 0.0031 0.0334 ± 0.0044 
         
SIALYLATED         
         
Jejunum4         
12h 0.0004 ± 0.0003 0.0008 ± 0.0005 0.0005 ± 0.0004 0.0004 ± 0.0003 
72h 0.0010 ± 0.0006 0.0017 ± 0.0009 0.0006 ± 0.0004 0.0021 ± 0.0012 
         
Ileum5         
12h 0.0027 ± 0.0006 0.0035 ± 0.0006 0.0019 ± 0.0006 0.0008 ± 0.0006 
72h 0.0015 ± 0.0006 0.0005 ± 0.0005 0.0024 ± 0.0005 0.0021 ± 0.0006 
         
 
1 All values are mean ± SEM expressed as relative goblet cell number per depth and is adjusted to include sulfated and sialylated  
fractions of mixed cells.  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in SAS 9.1 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, 9Bu was greater than control, (treatment main effect, p=0.047).   
4 Within this dependent variable, 72h tended to be greater than 12h (time main effect, p=0.058).   
5 Within this dependent variable, control was greater than SCFA at 12h; however this difference was not seen at 72h (p=0.0004).
 58
Table 2.7: Effect of short-chain fatty acid supplemented total parenteral nutrition on muc2 mRNA following massive small bowel 
resection in neonatal piglets1,2 
TREATMENT 
 Control 9 Bu 60 Bu SCFA 
             
         
Jejunum3         
12h 0.571 ± 0.193 2.112 ± 0.788 0.775 ± 0.225 0.930 ± 0.269 
72h 0.878 ± 0.254 1.138 ± 0.336 0.800 ± 0.232 0.578 ± 0.195 
         
Ileum4         
12h 0.885 ± 0.264 0.723 ± 0.264 1.004 ± 0.264 0.562 ± 0.264 
72h 0.883 ± 0.264 1.494 ± 0.264 1.052 ± 0.262 1.138 ± 0.262 
         
Colon         
12h 0.508 ± 0.187 0.461 ± 0.226 0.671 ± 0.083 0.593 ± 0.156 
72h 0.636 ± 0.167 0.712 ± 0.187 0.446 ± 0.118 0.556 ± 0.146 
         
 
1 All values are mean ± SEM expressed as muc2 mRNA/18S mRNA.  Data were analyzed statistically as one-tailed t-tests in  
split-plot design using the mixed model in SAS 9.1. 
2 Abbreviations: 9 mM butyrate (9Bu), 60 mM butyrate (60Bu), 60 mM short chain fatty acid (SCFA). 
3 Within this dependent variable, 9Bu was greater than control (treatment main effect, p=0.010). 






Figure 2.1: Gel electrophoresis.  DNA ladder is present in the left lane with the bottom four bands being 50 base pairs, 100 base pairs,  
150 base pairs, and 200 base pairs.  The product of rt-PCR of the cDNA of all samples pooled is in the right lane and contains both 18S 
and muc2 amplicon.  The 18S DNA amplicon is 187 base pairs which is present as a faint band.  The muc2 amplicon is 64 base pairs and  
is not visible in the right lane.
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Figure 2.2: Periodic acid schiff’s alcian blue (PASAB) stain of ileal tissue from a 72h piglet receiving 9Bu treatment.  Image is at 10x 








Figure 2.3: PASAB stain of ileal villi from a 72h piglet receiving 9Bu treatment.  Image is at 40x magnification.  PASAB colors neutral 
mucins pink and acidomucins blue.  Goblet cells were counted in one of the 5 following groups: 1.) 100% acidic mucin; 2.) 75% acidic 
mucin and 25% neutral mucin; 3.) 50% acidic mucin and 50% neutral mucin; 4.) 25% acidic and 75% neutral mucin; and 5.) 100%  
neutral mucin.  These mixed goblet cells were assigned to the group that most closely matched their composition.   
75% acidic mucin, 25% neutral mucin 









Figure 2.4: High iron diamine alcian blue (HIDAB) stain of jejunal tissue from a 12h control piglet.  Image is at 10x magnification.  
HIDAB stain colors sulfomucins brown and sialomucins blue.   
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 75% sulfomucin; 25% sialomucin  
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Figure 2.5: High iron diamine alcian blue (HIDAB) stain of jejunal crypts of a 12h control piglet.  Image is at 40x magnification.   
HIDAB stain colors sulfomucins brown and sialomucins blue.  Goblet cells were counted in one of the 5 following groups: 1.) 100% 
sulfomucin; 2.) 75% sulfomucin and 25% sialomucin; 3.) 50% sulfomucin and 50% sialomucin; 4.) 25% sulfomucin and 75%  
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Figure 2.6: Effect of SCFA and Bu supplementation on ileal crypt acidomucin chemotypes. 
Data is expressed as relative goblet cell number per depth and is adjusted to include neutral and 
acidic fractions of mixed cells. *Adjusted acidic goblet cell number was greater in the 60Bu 
treatment group than control (treatment main effect, p=0.038). Data were analyzed statistically as 
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Figure 2.7: Effect of SCFA and Bu supplementation ileal villus acidomucin chemotypes. 
Data is expressed as relative goblet cell number per height and is adjusted to include neutral and 
acidic fractions of mixed cells. *Significantly different than respective control group (p=0.031).  
Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed model in  
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Figure 2.8: Effect of SCFA and Bu supplementation on colonic crypt sialomucin 
chemotypes. Data is expressed as relative goblet cell number per depth and is adjusted to include 
sulfated and sialated fractions of mixed cells.  *Significantly different than respective control group 
(p=0.039).  Data were analyzed statistically as one-tailed t-tests in split-plot design using the mixed 
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Figure 2.9: Effect of SCFA and Bu supplementation on jejunal villus sulfomucin 
chemotypes. Data is expressed as relative goblet cell number per height and is adjusted to include 
sulfated and sialated fractions of mixed cells. *Sulfomucin chemotypes are greater in 9 Bu than 
control (treatment main effect, p=0.047). Data were analyzed statistically as one-tailed t-tests in  
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Figure 2.10: Effect of SCFA and Bu supplementation on jejunal muc2 mRNA. Data is 
expressed as muc2 mRNA/18s mRNA.  *The 9Bu group had greater muc2 mRNA than control, 
(treatment main effect, p=0.010). Data were analyzed statistically as one-tailed t-tests in split-plot 








SBS and PN administration both contribute to intestinal barrier dysfunction and bacterial 
translocation, and these data demonstrate butyrate’s effectiveness in improving innate barrier 
defense and presents a promising treatment for decreasing rates of bacterial translocation.  Within 
this study, exploring bacterial infection in the surrounding lymph nodes and the liver and kidneys 
would be an interesting avenue of study to elucidate whether the increases in protective goblet cell 
chemotypes observed in piglets receiving SCFA and butyrate supplementation decreased bacterial 
translocation.  Additionally, to be sure that any decreases in bacterial infection are attributed to 
increases in protective mucins, tight junction protein abundance and mRNA expression could also 
be assessed.   
Since PN is much more common than TPN, the effect of butyrate and SCFA administration 
on goblet cell chemotypes and muc2 in the presence of EN is an important relationship to establish.  
This avenue would also be important to explore since practitioners try to avoid TPN with most SBS 
infants and instead try to administer some EN to maintain as much bowel function as possible.  
Because butyrate has been shown to have profound effects on mucin production when administered 
luminally (Finnie et al., 1995; Willemsen et al., 2003; Gaudier et al., 2004; Hatayama et al., 2007), and 
PN is associated with decreased mucin production (Iiboshi et al., 1994; Bertolo et al., 1998; Law et 
al., 2007), the positive effects of PEN in conjunction with parenteral butyrate or SCFA 
administration on protective goblet cell chemotypes and muc2 mRNA could be additive.   
To study the effects of butyrate administration in addition to EN, butyrate could clinically 
only be supplied parenterally, as butyrate is not tolerable as an oral solution.  However, oral 
administration of tributyrin is a possibility.  Tributyrin is a prodrug form of butyrate which means 
that it is inactive until metabolized, at which time it becomes an active metabolite.  Tributyrin has 
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been shown to be tolerated in an adult clinical trial and 3 daily oral dosings can attain in vitro levels of 
butyrate seen in many studies (Edelman et al., 2003).  Tributyrin confers positive effects on intestinal 
morphology by increasing villus height and crypt depth when administered with a fermentable 
substrate in pigs (Piva et al., 2002; Piva et al., 2008).  Further, administration of a 1:1 mixture of 
triacetin and tributyrin in rats with 60% bowel resection and cecectomy has been demonstrated to 
significantly increase jejunal mucosa, all intestinal segmental weights, and all intestinal segmental 
protein levels (Kripke et al., 1991).  While in this study it cannot be determined if the positive effects 
on intestinal adaptation are due to tributyrin rather than triacetin, this is expected to be the case due 
to all the literature stating specifically butyrate’s positive effects on intestinal adaptation (Tappenden 
et al., 1997; Bartholome et al., 2004; Hamer et al., 2008) and recent findings supporting butyrate’s 
relationship with proglucagon and intestinotrophic GLP-2 (Woodard and Tappenden, 2008).   
Another method to increase butyrate availability to the intestinal epithelium is to increase its 
endogenous production.  This can be done by feeding fermentable fiber along with PEN that is then 
digested by the resident microbiota to create SCFAs, including butyrate (Bourquin et al., 1993; 
Kapadia et al., 1995).  Additionally, some fibers increase butyrate production more than others 
(Kapadia et al., 1995).  This method may be less direct than administration of a prodrug; however, it 
has other benefits.  Feeding certain fibers not only increases SCFA production, but can also change 
the composition of the intestinal microbiota by increasing the density of the resident microbes, 
which can decrease the growth of harmful microbes such as Clostridium difficile (May et al., 1994).  
Increasing butyrate production and potentially protective mucins could also decrease growth of 
harmful bacteria, which would be obviously beneficial in a short bowel syndrome infant at risk for 
bacterial translocation.  Both animal studies and clinical studies exploring the effects of tributyrin 
and fiber administration are needed to validate the effectiveness of these methods on mucin 
production and on possible subsequent prevention of bacterial translocation. 
 71
 72
In addition, the mechanism by which butyrate increases mucin production needs to be 
explored.  It may be that butyrate increases or decreases an intermediate factor that affects mucin 
production such as affecting mRNA or protein expression of sulfotransferases or sialotransferases.  
If there is an intermediate factor, its discovery would allow expedited clinical targeting of increasing 
mucin production. 
 In summary, the area of mucin modulatioin via SCFAs and butyrate is novel and much is yet 
to be discovered.  Butryate is a promising supplement to potentially improve the clinical outcomes 
of the SBS pediatric population via improved barrier defense.
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